



**HAL**  
open science

## **The challenge of gene therapy for neurological diseases: strategies and tools to achieve efficient delivery to the central nervous system**

Timothée de Saint Denis, Françoise Piguet, Emilie Audouard, Kevin Beccaria,  
Arthur André, Guillaume Wurtz, Raphael Schatz, Sandro Alves, Caroline Sevin,  
Michel Zerah, et al.

### ► To cite this version:

Timothée de Saint Denis, Françoise Piguet, Emilie Audouard, Kevin Beccaria, Arthur André, et al.. The challenge of gene therapy for neurological diseases: strategies and tools to achieve efficient delivery to the central nervous system. *Human Gene Therapy*, 2021, 32 (7-8), pp.349-374. <10.1089/hum.2020.105>. <hal-03265982>

**HAL Id: hal-03265982**

**<https://hal.sorbonne-universite.fr/hal-03265982v1>**

Submitted on 21 Jun 2021

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



HAL Authorization

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32

**The challenge of gene therapy for neurological diseases: strategies and tools to achieve efficient delivery to the central nervous system**

Françoise Piguet<sup>1#\*</sup>, Timothée de Saint Denis<sup>1,2#</sup>, Emilie Audouard<sup>1</sup>; Kevin Beccaria<sup>1,2</sup>, Arthur André<sup>1,3</sup>, Guillaume Wurtz<sup>1</sup>, Raphael Schatz<sup>1</sup>, Sandro Alves<sup>4</sup>, Caroline Sevin<sup>1,4</sup>, Michel Zerah<sup>1,2#\*</sup> and Nathalie Cartier<sup>1#\*</sup>

**Authors affiliations**

- 1 NeuroGenCell, INSERM U1127, Paris Brain Institute (ICM), Sorbonne University, CNRS, AP-HP, University Hospital Pitié-Salpêtrière, Paris, France.
- 2 APHP, Department of Pediatric Neurosurgery, Hôpital Necker-Enfants Malades, APHP Centre. Université de Paris
- 3 APHP, Department of Neurosurgery, Hôpitaux Universitaires La Pitié-Salpêtrière, Sorbonne Universités, UPMC Univ Paris 6, Paris, France
- 4 Brainvectis Therapeutics, iPeps Paris Brain Institute, Paris, France
- 5 APHP, Department of Neurology, Hopital le Kremlin Bicetre, Kremlin Bicetre, France.

# These authors equally contributed to the work

\*Corresponding authors:

- Françoise Piguet [francoise.piguet@icm-institute.org](mailto:francoise.piguet@icm-institute.org)
- Michel Zerah [michel.zerah@aphp.fr](mailto:michel.zerah@aphp.fr)
- Nathalie Cartier [nathalie.cartier@inserm.fr](mailto:nathalie.cartier@inserm.fr)

**Abstract**

For more than ten years, gene therapy for neurological diseases has experienced intensive research growth and more recently therapeutic interventions for multiple indications. Beneficial results in several phase 1/2 clinical studies, together with improved vector technology have advanced gene therapy for the central nervous system (CNS) in a new era of development. While most initial strategies have focused on orphan genetic diseases, such as lysosomal storage diseases, more complex and widespread conditions like Alzheimer’s disease, Parkinson’s disease, epilepsy or chronic pain are increasingly targeted for gene

1 therapy. Increasing numbers of applications and patients to be treated will require improving  
2 and simplifying gene therapy protocols to make them accessible to the largest number of  
3 affected people. While vectors and manufacturing are a major field of academic research and  
4 industrial development, there is a growing need to improve, standardize and simplify delivery  
5 methods. Delivery is the major issue for CNS therapies in general, and particularly for gene  
6 therapy. The blood brain barrier restricts the passage of vectors; and strategies to bypass this  
7 obstacle are a central focus of research. Here, we present the different ways that can be used  
8 to deliver gene therapy products to the CNS. We focus on results obtained in large animals  
9 that have allowed the transfer of protocols to human patients and have resulted in the  
10 generation of clinical data. We discuss the different routes of administration, their advantages  
11 and their limitations. We describe techniques, equipment and protocols and how they should  
12 be selected for safe delivery and improved efficiency for the next generation of gene therapy  
13 trials for CNS diseases.

14

## 15 ***Introduction***

16 The central nervous system (CNS) is protected by a unique microvasculature, the  
17 blood-brain-barrier (BBB), composed of endothelial cells connected by tight junctions and  
18 adherent processes. The BBB controls brain homeostasis as well as ion and molecule  
19 movements thus protecting the CNS against potential intruders. The restrictive nature of the  
20 BBB provides an obstacle for drug delivery to the CNS, and major efforts have been made to  
21 generate methods to modulate or bypass the BBB for delivery of therapeutics. Contrarily,  
22 some pathologies of the CNS including stroke, multiple sclerosis, brain traumas and  
23 neurodegenerative disorders, alter the BBB causing it to become more permeable, allowing  
24 the entry of molecules that can induce inflammatory responses and lead to neuronal  
25 damage<sup>1,2</sup>.

26 Gene therapy has been applied to several CNS diseases, including neurodegenerative<sup>3</sup>  
27 and neurodevelopmental disorders<sup>4,5</sup>, but also increasingly for diverse conditions such as  
28 epilepsy<sup>6</sup>, glioblastoma<sup>7</sup> and pain<sup>8</sup>. Increasingly, gene therapy products can be tailored to  
29 counter the pathophysiological mechanisms of particular disease mechanism, including the  
30 use of gene replacement<sup>9-11,12,13</sup>, gene silencing<sup>14</sup>, transplicing<sup>15</sup>, modulation of cellular  
31 pathways to improve phenotype<sup>16-19</sup> or expression of suicide gene<sup>20</sup>.

1 Gene therapy products can be delivered by various routes of administration, using  
2 either *ex vivo* or *in vivo* strategies. *Ex vivo* gene therapy involves autologous transplantation  
3 of hematopoietic stem cells corrected by genetic modification of lentivirus (HSC-GT) outside  
4 the body and subsequent transplantation of the cells back into the patient. HSC-GT has shown  
5 Efficacy for HCS-GT has been shown in clinical trials for leukodystrophies (ALD, MLD)<sup>21,22</sup>.  
6 Therapeutic action involves either production of the therapeutic protein by donor derived  
7 cells that can migrate into the CNS (permanent source of the missing enzyme), and/or  
8 modulation of the immune environment (replacement of microglial cells and/or perivascular  
9 macrophages). *In vivo* gene therapy requires direct introduction of the vector (carrying the  
10 therapeutic gene) into the patient (Figure 1). Intravenous administration is a common route  
11 of administration for *in vivo* gene therapy but for CNS diseases the the limited capacity of  
12 gene delivery systems to cross the BBB remains a significant obstacle Strategies such as  
13 disruption of the BBB integrity (by osmotic or biochemical means) or improvement of viral  
14 vector capsids continue to be developed toto enhance peripheral administration. Direct  
15 delivery into the parenchyma of the brain or the cerebrospinal fluid (CSF) bypasses the BBB  
16 and permits more targeted gene delivery . Following intrathecal or intracerebroventricular  
17 administration, the therapeutic vector enters the cerebrospinal fluid and is delivered  
18 throughout the CNS (at least to tissue adjacent to CSF spaces). Following intraparenchymal  
19 administration, the therapeutic vector enters the brain parenchyma and is delivered locally  
20 into brain cells. The diffusion of the therapeutic product is limited around the injection site;  
21 however, secretion-uptake may improve diffusion, notably the case for most lysosomal  
22 storage disease enzymes.

23 The vector of choice for *in vivo* CNS delivery is the adeno-associated viral (AAV) vector.  
24 Recombinant AAVs have been widely used for CNS gene therapy, demonstrating safety, stable  
25 and long-term expression and some degree of neuronal tropism relevant for many therapeutic  
26 applications. A large body of preclinical results have been obtained, particularly in large  
27 animals like dogs, cats and non-human primates that have demonstrated feasibility for clinical  
28 use<sup>23</sup>.

29 Wild-type AAVs are non-enveloped parvovirus, which are characterized by an  
30 icosahedral capsid and a 4.7 kb single stranded DNA genome. To complete a replication cycle,  
31 AAVs require coinfection by a helper virus like adenovirus or herpes virus. AAVs infect humans  
32 and other species including the non-human primate (NHP)<sup>24</sup>. Natural infection with AAV is not

1 known to lead to disease, although there is controversy concerning hepatocellular  
2 carcinoma<sup>25,26</sup>. The minimal sequence needed to generate Recombinant AAVs is restricted to  
3 the 145 bp within the inverted terminal repeats (ITRs) flanking the transgene<sup>27</sup>. The overall  
4 capacity of AAV to package an ITR-flanked genome productively is the approximate size of the  
5 wild-type AAV genome (i.e., 4.7 kb).

6 Overall AAV vectors have been used and have proven their safety and low immunogenicity  
7 tolerance in more than 200 human studies<sup>28</sup>. Efficiency of an AAV administration is  
8 determined mainly by the capsid, that directs the tropism of the virion, but can be impacted  
9 by the route of administration<sup>29</sup>. It is also well established that the specificity of transgene  
10 expression is dependent on both the capsid and the regulatory elements present in the  
11 vector<sup>30</sup>. There are a large number of AAV serotypes based on capsid structure<sup>31</sup>. AAV2, the  
12 first AAV serotype to be used as a replication-defective vector, has been the most extensively  
13 characterized. Other AAV serotypes developed later as vectors, employ a cross-packaging  
14 system, in which genomes flanked by AAV2 ITRs are packaged in other AAV capsids. These  
15 serotypes have a wide variety of tissue and cell tropism<sup>32</sup>. For gene transfer to the CNS the  
16 most frequently used capsids have been AAV1<sup>33</sup>, AAV2<sup>34-36</sup>, AAV5<sup>37</sup>, AAV9<sup>12</sup> and AAVrh.10<sup>9,38</sup>.  
17 AAV9 was shown to naturally cross the BBB and allowing for widespread, but  
18 limited expression of therapeutic genes in the CNS after a single intravenous injection of  
19 vector<sup>39,40</sup>. Importantly, the first clinical report of gene-replacement therapy for SMA type I  
20 has demonstrated the safety and efficacy of this approach<sup>41</sup>. However, the efficacy of brain  
21 transduction efficacy may vary with the patient age at treatment. Ongoing efforts to engineer  
22 capsids with improved capacity to cross the BBB. AAV variants<sup>42,43</sup> such as AAV.PHP.B and  
23 AAV-B1<sup>41,44</sup> have resulted in superior capacity for CNS targeting, at least in the animal models  
24 tested<sup>45</sup>.

25 Lentiviral vectors (LV) are members of the Retroviridae family, and based either on human  
26 immunodeficiency virus (HIV), non-primate primates (SIV), or others such as equine infectious  
27 anemia virus (EIAV)<sup>46</sup>. The viral genome contains two long terminal repeats (LTR), with  
28 elements required for gene expression, reverse transcription and integration into host  
29 chromosome<sup>47</sup>. For safety and efficacy, third generation of LVs do not have viral genes. Gag,  
30 Pol and Rev genes are present in the packaging construct that allow the production of the  
31 recombinant vector but not in the transgene construct. Different pseudotypes of LV with  
32 different envelopes allowing for different viral tropism have been developed. The most

1 frequently used is the vesicular stomatitis virus glycoprotein (VSV-G), which has a broad  
2 tropism *in vitro* and neuronal and glial tropism *in vivo*<sup>48,49</sup>. Lentiviruses are able to penetrate  
3 the intact nuclear membrane through nuclear pores, do not require cell division and can  
4 efficiently infect quiescent cells<sup>50,51</sup>. This ability to transduce dividing and non-dividing cells,  
5 long-term stable expression through transgene integration into the chromosomes of host  
6 cells, and their large cloning capacity make LVs desirable vectors for gene therapy<sup>52</sup>. They also  
7 have a cloning capacity of 9.7kb.

8 LVs are particularly useful for ex vivo gene therapy applications. Hematopoietic stem  
9 cells (HSCs) can be stably transduced using lentiviral vectors; allowing for stable, indefinitely  
10 persisting expression within the host cell, despite repeated cell division. This characteristic has  
11 been widely applied to CNS lysosomal storage diseases or Adrenoleukodystrophy<sup>53,54</sup>. Random  
12 integration in the genome of host cells is associated with a potential genotoxicity risk, as  
13 previously observed with retroviruses<sup>55,56</sup>. However, long-term follow-up of gene therapy  
14 trials has not identified adverse events associated with insertional mutagenesis<sup>57-59</sup>. *In vivo*  
15 use of lentivectors for CNS applications has been more limited. Because of their capacity to  
16 transduce neurons, they have been tested for the treatment of Alzheimer's disease (AD) and  
17 Parkinson's disease (PD)<sup>60-62</sup>. For this review, we focused more on AAV since they have been  
18 more widely used in CNS targeting for large animals and human clinical trials.

19

### 20 ***Evaluation of administration routes in preclinical studies***

21 Translation to clinical application after proof-of-concept in mouse models of the  
22 disease most often requires efficacy and tolerance studies in large animals.

23 Many species have been used<sup>63</sup> for preclinical development. Affinity for the different  
24 types of brain cell in large animal species remains a major issue. The choice of the large  
25 animal model to be used is mainly based on the use of a large animal model of the disease  
26 when available<sup>64-67</sup> otherwise on anatomical aspect to mimic the best situation to be  
27 reproduced for future clinical trials.

28 When the gene therapy product is administered by injection in the blood stream or the  
29 CSF any suitable species of large animal can be employed. However, when delivery is based  
30 on direct intra-parenchymal injection into the brain for characterizing biodistribution, toxicity,  
31 diffusion, affinity with different types of brain cells, pigs, sheep and non-human primates  
32 (NHP) are preferred species for modeling trajectories and efficient targeting. In all cases it

1 must be emphasized that the use of large animals is strictly limited for ethical reasons and  
2 should be performed in GLP or GLP-like conditions to be usable for regulatory documents.

#### 3 4 Intraparenchymal delivery

5 The principle studies of intra-parenchymal (IP) gene delivery in large animals are  
6 summarized in Table 1. Direct IP injection – either direct perfusion or convection enhanced  
7 delivery (CED)- allows targeted delivery in CNS regions while bypassing the BBB. However, IP  
8 injections remain more complex to perform than ICV or IT techniques for several reasons<sup>69</sup>.  
9 The choice of the target region is always a challenging balance between efficacy and safety.  
10 Therefore, the specific anatomy as well as pathophysiology of the disease should be  
11 considered when choosing target sites.. Targeting the white matter in multiple sites may  
12 enhance vector spreading<sup>11</sup>. In particular, AAV vectors are readily transported along axons  
13 which facilitate the distribution of the therapeutic gene<sup>70</sup>. The spreading and directionality of  
14 AAV transport are serotype-dependent<sup>71</sup>. AAV2, which has been widely used in IP gene  
15 delivery, resulted in anterograde transport<sup>72</sup> of vector particles from basal ganglia to cortex  
16 in NHP<sup>73,74</sup>. In contrast, AAV6 is axonally transported exclusively in a retrograde  
17 direction<sup>72</sup> while AAV9 shows a bidirectional transport and is dose dependent<sup>75</sup>.

18 Recent studies suggest that AAV5 and AAVrh10 have more global transduction with  
19 widespread distribution in the brain<sup>11,76,77</sup> and spinal cord. Lentiviral vectors are able to deliver  
20 the therapeutic gene in a restricted area<sup>78,79</sup>.

#### 21 22 Intracerebrospinal fluid delivery

23 As an alternative to intraparenchymal delivery and to target larger brain or spinal cord  
24 volumes, especially in neurodegenerative diseases involving widespread regions, an  
25 alternative to intraparenchymal injection is intra-CSF delivery.

26 For this purpose, three major routes can be used: intracerebroventricular delivery into  
27 the ventricles, the cisterna magna as widely used in large animal models (Table 1) or by  
28 intrathecal delivery into the CSF surrounding the spinal cord (Table 2).

29 Lentiviral vectors have been used in one approach in adult sheep, but this reported  
30 attempt resulted in very limited transduction close to the needle track with up to 2.5mm  
31 rostro-caudal transduction<sup>80</sup>. AAVs lead to greater transduction especially in adults. ICV  
32 delivery in young animals differ, providing extensive transduction of motorneurons in some

1 cases. Using scAAV9 in 5-days old pigs<sup>81</sup> and in 10-11 days old dog, Katz et al. reported a TPP1  
2 activity increase in CSF a few days after transduction, but then loss of the transgene due to  
3 immune response against the transgene product<sup>82</sup>. AAV9 and AAVrh10 have been  
4 predominantly injected with doses ranging from  $10^{12}$ vg to  $5.10^{13}$ vg in dogs, NHP and cat<sup>70,83-</sup>  
5 <sup>91</sup> mainly in the *cisterna magna* with either GFP or therapeutic genes (Table 2). Diffuse  
6 transgene expression was obtained in the cortex and cerebellum (Table 2). In most studies,  
7 efficacy of spinal cord targeting was not analyzed; however, available studies report highly  
8 variable results with large motoneuron transduction<sup>92</sup>.

9 As an alternative to ICV delivery or depending on the pathology to improve spinal cord  
10 targeting, delivery in the CSF can be achieved through intrathecal injection. Studies have been  
11 performed in dogs<sup>89,93,94</sup>, NHP<sup>13,88,95</sup>, pigs<sup>87,96</sup> and marmosets<sup>97</sup> mainly using AAV9 or AAVrh10  
12 vector in neonates (5 day-old) to adult animals (Table 3). Two major techniques are routinely  
13 used for intrathecal delivery, either a single delivery without the use of a catheter, generally  
14 performed in the L4/L5 space, or with prior insertion of a catheter to allow either single or  
15 multiple deliveries<sup>87,98</sup>. Intrathecal delivery leads to efficient motoneurons transduction with  
16 efficiency ranging from 10-30%<sup>87</sup> to 80%<sup>13</sup> depending on the study (Table 3), but sparse  
17 transduction in the brain (Table 3). Two studies have evaluated placing the animal in the  
18 Tredelenburg position with the feet elevated above the level of the head to improve the  
19 upward diffusion of the vector. Variable results were reported, one showing no  
20 improvement<sup>99</sup> and the other one a slight increase, with up to 55% targeting of cervical  
21 motoneurons<sup>13</sup> (Table 3).

22 Even if ICV delivery is designed to target basal ganglia (Figure 1d), intracisternally to  
23 target the cortex (Figure 1c) and intrathecal delivery for the spinal cord (Figure 1b), the direct  
24 relationship between the site of injection and the efficient delivery to the target has never  
25 been proven, and appear to differ between NHP and human in relation to the volume of  
26 the respective brains and the distance between CSF pathways and the CNS targets.

27 In between intraparenchymal and intra-CSF delivery, for intraspinal targets, spinal  
28 subpial delivery has been proposed in mice, rats and pigs<sup>100,101</sup>. Despite the short distances  
29 for spinal diseases, the primary issues remain the need for an open micro-neurosurgical  
30 approach following laminectomy (or a laminotomy) and the risk of neurological deficits  
31 secondary to spinal cord subpial bleeding.

32

## 1 Intravenous delivery

2 As an alternative to more invasive injections, IV delivery has recently become an option  
3 to target the CNS, especially with the SMN trial<sup>41</sup>. AAV9 and AAVrh10 are once again the major  
4 serotypes injected dosing from  $10^{12}$ vg/kg up to  $10^{14}$ vg/kg. In neonates (2 to 7 days-old) studies  
5 have demonstrated up to 39% transduced motoneurons in cats<sup>81</sup> but other studies were  
6 unable to detect the transgene<sup>92</sup> (Table 4). In adults differ with mild to no neuronal  
7 transduction<sup>85,94</sup> either in spinal cord and brain (Table 4). Transduction was in any case much  
8 lower compared to ICV<sup>88</sup> or intrathecal delivery and glial cells were predominantly transduced  
9 <sup>90,96</sup>, without clear explanation.. In addition, IV delivery led to an significant transduction of  
10 peripheral organs (Table 4).

## 11

## 12 ***Routes of administration in clinical studies***

13 While intravenous delivery is readily transferred from animal models to human trial  
14 conditions, CSF or brain delivery techniques must be carefully adapted for human conditions  
15 (brain anatomy and volumes). ICV, cisternal and intrathecal methods, can however all be used  
16 in human subjects. There is very little intraventricular vector diffusion after cisternal or  
17 intrathecal injection; most of the product remains in the spinal compartment or reaches the  
18 peri-cerebral space. Because of the size of the brain and the distance between the ventricles  
19 and the cortex, it is impossible to achieve consequent and homogenous diffusion by any CSF  
20 route.

21 Intraparenchymal injection is possible in the human brain, in deep nuclei, or in the white  
22 matter (but may need multiple simultaneous injections to obtain sufficient diffusion), but  
23 there is no reliable technique for delivering to the spinal cord parenchyma.

24 The doses of vector delivered depends on the route of administration. While  
25 intraparenchymal delivery requires small amounts of vector ranging from  $10^9$  to  $2.5 \cdot 10^{12}$  total  
26 vg in NHP and human, doses from  $10^{12}$  to  $5 \cdot 10^{13}$  vg are required for ICV or intrathecal delivery.  
27 Intravenous delivery dramatically increases the number of particles required; from  $5 \cdot 10^{12}$  to  
28  $5 \cdot 10^{14}$  vg ( $10^{12}$  to  $10^{14}$  vg/kg) in NHP and close to  $10^{15}$  vg in patients in the SMA trial ( $2 \cdot 10^{14}$ /kg)  
29 (see tables 1-6).

30 Local administration of low doses of vector limits biodistribution and the risk of  
31 immunogenicity or toxicity due to AAV capsid or expression of the transgene. The high doses

1 required for intra-CSF and IV administration raise issues of immunogenicity, manufacturability  
2 and final cost.

3 Translating gene therapy proof of concept in animal models to clinical application in  
4 patients requires adapting delivery protocols. Translation may be simple for intra-CSF or IV  
5 delivery, based on the weight of the animal or the volume of the brain tissue or of the CSF.  
6 Modeling the delivery into the brain parenchyma is more critical for designing a clinical  
7 protocol. This should take into consideration the volume of the target region determined by  
8 imaging, the sites and the number of injections, the degree of anatomical precision required,  
9 the volumes to be injected, and the flow (constant or CED). Translating these parameters from  
10 large animal brain to human brain requires specific anatomical adaptations (needle track in  
11 particular) and evaluation of feasibility, safety and efficiency in terms of biodistribution in  
12 animal models under conditions as close as possible to the human clinical procedure.

13 There is no limits for age, and theoretically, it is possible to treat even newborns by all  
14 routes of delivery. It is possible to use frameless stereotactic delivery using magnetic or optic  
15 neuronavigation. In addition, robotic systems are now available even in the youngest subjects.  
16 The youngest child treated by our team with intracerebral delivery (16 targets supra and  
17 infratentorial) was 9 month-old<sup>9</sup>.

18

### 19 Intra cerebro-spinal fluid delivery

20 To overcome the inability of the gene therapy vectors to cross the BBB, direct injection within  
21 the CNS compartment has been attempted<sup>102</sup>. All trials using these routes of administration  
22 are summarized in Table 5. Three main modalities can be discussed:

- 23 • Intrathecal lumbar administration with 2 potential modalities:

24 (1) Direct unique injection by a lumbar tap or through an intraspinal catheter  
25 connected to a subcutaneous reservoir. The use of a single injection by lumbar  
26 tapping is a non-surgical procedure. It could be done, in a medical environment,  
27 with local anesthesia. In difficult cases, the use of Fluoroscopy or  
28 Ultrasonography<sup>68</sup> can facilitate the procedure (or to guide a catheter insertion).  
29 The main inconvenience of this technique is the risk of CSF leak in the extradural  
30 space at the moment of needle removal and the one to two days post procedure.  
31 Consequently, it is impossible to precisely control the quantity of vector

1 administered within the intradural space. The use of atraumatic G22 needle  
2 (Sprotte) can minimize this risk<sup>68</sup>.

3 (2) To avoid this major inconvenience, the alternative is to install a subcutaneous  
4 reservoir connected to an intraspinal catheter<sup>68</sup>. This procedure must be done in  
5 the operative room, under general anesthesia. Injection must be performed one  
6 or two weeks after the initial surgery and the removal of the system at least one  
7 week after. This technic guaranties control of the injected volume, but needs two  
8 general anesthetics and increases the risk of infection. The main incertitudes of  
9 this technique is determining the exact distribution of the product between the  
10 different compartments; intraspinal CSF, intraventricular and intracranial  
11 subarachnoidal spaces (Figure 1). The main disadvantage of the ITL access results  
12 from the natural flow of CSF from the intraventricular choroid plexus to the  
13 subarachnoid space around the spinal cord and finally to the pericerebral spaces  
14 for resorption through the venous system. Reaching the brain target through the  
15 CSF stream requires a large dose volume. Other associated strategies can be used  
16 to improve the efficacy such as a buffer flush or a Tredelenburg position.  
17 Complications due to the device and its implantation also have to be considered.  
18 Meningitis can be a severe infectious complication that needs removal of the  
19 system and adapted antibiotics treatment. Other mechanical complication can be  
20 encountered such as migration, rupture or disconnection, kinked or obstructed  
21 catheter. A CSF leak around the catheter to the subcutaneous space can lead to an  
22 artificial meningocele that can impair the ability to infuse the treatment. To  
23 overcome this problem, two other modes of administration have been proposed.

24 • Intracisternal administration<sup>103,104</sup>:

25 In most cases, it is possible to inject within the cisterna magna at the level of the  
26 craniovertebral junction. Even if it is possible to do it while the patient is awake,  
27 general anesthesia will be preferred, especially in the pediatric population. The risk of  
28 leakage is very low through this route and in most cases the reservoir is useless.

29 • Intraventricular administration

30 A third way route to the CSF space is to inject directly within the cerebral ventricles.  
31 In most cases, it will be done in the frontal horn by direct puncture under stereotactic  
32 guidance or more frequently now under frameless neuronavigation. In adults, it is

1 easily doable under local anesthesia and light sedation, in the pediatric population  
2 general anesthesia is preferable. Installation of an intraventricular catheter  
3 connected to a reservoir may be preferred, however for a single injection, direct  
4 injection is safe and efficient. It is also better for controlling the volume of injection  
5 and its distribution. However, because of the risk of parenchymal bleeding, most  
6 authors prefer the cisternal approach.

### 7 Intraparenchymal delivery

8 Few human trials using the intracerebral route are reported (Table 6); Both in adults  
9 (Huntington, Parkinson and Alzheimer diseases) and children (SMA, Canavan, Batten,  
10 mucopolysaccharidosis, MLD). The vast majority of the trials have employed AAV vectors  
11 (from  $10^7$  to  $10^{13}$ vg) with injections in the deep grey nuclei or in the white matter (only for  
12 metabolic diseases in children). Most published trials are Phase 1/2 and one is phase 3. Several  
13 studies obtained promising results even if partial or preliminary. Importantly, few severe  
14 adverse events have been reported.

### 15

### 16 **Technical aspects: state of the art**

17 Regarding delivery technique, we focus here on intracerebral delivery, indeed, other routes  
18 of delivery have been largely described previously and have not been researched as  
19 intensively.

### 20 Devices for intraparenchymal delivery of therapeutics agents

21 Intraparenchymal drug delivery systems offer a practical method for bypassing the BBB  
22 to deliver gene therapy. Direct access to parenchyma allows delivery at doses and  
23 concentrations that would otherwise correspond to very high levels and volumes systemically.  
24 However, this method still has constraints and limitations. For more than ten years,  
25 considerable research has focused on developing methods to enhance drug delivery<sup>105</sup>,  
26 through dedicated intraparenchymal devices.

27 Principles: Intraparenchymal delivery has two principle challenges : minimize backflow  
28 along the injection device and promote optimal drug distribution<sup>106</sup>, often in a spherical tissue  
29 volume. The distribution volume depends on infusion flow rate, infusion volume and number  
30 of injection sites and the type of vector that is injected<sup>107</sup>. The occurrence of backflow depends  
31 on several variables including cannula radius, infuse flow rate, and tip location<sup>108</sup>. Indeed,

1 many parameters influence the safety and efficiency of infusion: infusion flow rate, cannula  
2 size, infusion volume, and drug molecular size/charge<sup>109</sup>. Variations in flow rate impact the  
3 location of infusate distribution. Lower infusion rates (under 1  $\mu\text{l}/\text{min}$ ) are associated with  
4 distribution localized primarily to the target tissue (they are used for focal injection in specific  
5 areas, mainly in grey matter nuclei) whereas higher infusion rates result in increased  
6 distribution into the surrounding parenchyma («overflow»)<sup>106,109</sup>. Several techniques have  
7 been proposed to increase infusion rates (up to 10  $\mu\text{l}/\text{min}$ ); among them the use of CED<sup>110</sup>  
8 (convection enhanced delivery) which appears to provide the best compromise for extensive  
9 diffusion with minimal local damage. They are used combined with multiple injections (up to  
10 16)<sup>9</sup> when the whole brain must be treated (lysosomal diseases)<sup>11</sup>. Increases in infusion rates  
11 raise the local pressure around the infusion site and also increases the extent of backflow.  
12 Cannula size seems to have no effect on distribution ; however, larger cannulas cause more  
13 tissue damages and therefore produce decreased resistance pathways along the brain  
14 parenchyma-catheter interface that are associated with increased rates of backflow<sup>109</sup>.

15 Catheters subtypes: Three kind of delivery devices can be distinguished : catheters  
16 derived from another use (especially intraventricular devices), «homemade» designed  
17 catheters<sup>11,38,105,111</sup> from teams experimenting with pre-clinical intracerebral drug delivery or  
18 for early clinical studies<sup>38</sup>, and more recently commercialized catheter for specific  
19 intraparenchymal use (often developed from the homemade devices, and for intracerebral  
20 chemotherapy). Principal available devices are described in Table 7.

21 Ventricular catheters (2–3 mm outer diameter) that have been implanted in clinical trials to  
22 treat glioma have failed to distribute effectively and have been linked to poor  
23 distributions<sup>112,113</sup> Microcatheters (less than 1mm outer diameter) seem more reliable, and  
24 all FDA approved catheters for CED belong to this category.

25 Design: Recent catheters have been designed to reach the goals of parenchyma  
26 delivery : minimize invasiveness through a minimal diameter tubing (Casanova), optimize  
27 infusion parameters to maximize distribution volume, and a reflux inhibiting feature is  
28 required to halt backflow along the catheter entry track<sup>112</sup>. All these characteristics are  
29 summarized in Table 7. Means to minimize backflow are the following : polymer-impregnated  
30 tips<sup>105,114</sup>; stepped-design cannula<sup>108,115,116</sup> Recessed-design cannula<sup>112,117</sup> (Bristol). Means to  
31 enhance delivery are: multiporous cannula, multiport catheters, mobile-tip catheter, balloon-  
32 type cannula. A ‘valve tip’ has been proposed to prevent blockage by occluding the inner bore

1 of the cannula with a stylet during insertion<sup>106</sup>. Another new advance is a multi-site delivery  
2 catheter with one single tube<sup>118</sup> (CMC, IMI) that allows multiple targeting points and more  
3 homogenous delivery in a three dimensional array.

4 Pumps and syringes: To enable injection of small volumes at precise, low speeds, specific  
5 pumps and syringes must be employed. For pumps, most are manufactured for research use  
6 (Harvard Apparatus, Holliston Massachusetts, USA), and special authorizations must be  
7 obtained for clinical use.

8 Injection systems: Combining precision delivery and limited procedure time.

9 Classical stereotactic technics are well adapted for injection in a unique site of brain  
10 parenchyma - however, new techniques allowing multiple brain injections of the gene therapy  
11 for many indications are needed. Specific 3D MR sequences allow precisetargeting in white  
12 matter or in deep grey matter nuclei (striatum, thalamus, caudate nucleus...). Preplanning  
13 using neuronavigation software (Medtronic® or Brainlab®) facilitates the choice of  
14 trajectories, modeling delivery and rehearsingthe surgical procedure. Optic or magnetic  
15 neuronavigation system with or without robotic tools (Rosa®, Renishaw®, Medtronic®,  
16 Brainlab®) allows frameless insertion of multiple cannulas, supra or infra-tentorially according  
17 to the preplanning. Altogether these systems allow the delivery of therapeutic product  
18 reproducibly with high precision (around 1mm). Intra-operative Real-time MRI has also been  
19 proposed as an additive tool to verify the position of the cannula and to check the diffusion of  
20 the product with simultaneous gadolinium injection<sup>119,120</sup>, albeit with the risk of long term  
21 toxicity.

22

### 23 ***Risks assessment***

#### 24 *Linked to the delivery procedure*

25 Risks due to anesthesia are mainly correlated to the disease itself and related  
26 comorbidities. All injections or catheter placement can result in a CNS injury or hemorrhagic  
27 complications. Lumbar puncture is at very low risk of complication if done at the low lumbar  
28 level without spinal cord anomalies such as low tethered cord. Epidural hematoma can occur,  
29 especially with repeated punctures. Spinal epidural hematoma can remain asymptomatic but  
30 sometimes cause radicular pain and even rare motor impairment or sphincter dysfunction in  
31 case of cauda equina syndrome. A motor impairment requires a surgical evacuation. Lumbar

1 puncture can cause subarachnoid bleeding leading to radiculitis, pain and headache. In case  
2 of spinal deformity, fluoroscopy or ultrasonography may help to guide the puncture.

3 Intrathecal catheter placement needs the use of a guide wire to conduct the catheter  
4 to the thoracic level or higher and can result in a spinal cord injury and cause motor or  
5 sensitive (transient in the vast majority of the cases) dysfunction. The risk of a hemorrhagic  
6 complication in the epidural or intradural space is higher in relation to the larger size of the  
7 needle.

8 Intracranial hypotension symptoms can occur secondary to a lumbar puncture and  
9 cause severe orthostatic headaches which can be managed with supine position, painkillers  
10 and if needed, blood transfusion.

11 Intracisternal puncture requires an adequate cisternal space (verified by MRI), a  
12 motionless situation and an experienced operator. The size of the cisterna magna and the  
13 shape of the skull, a Chiari anomaly or a foramen magnum stenosis increase the risk of  
14 neurological complication (Bulbomedullary junction injury responsible for cardiorespiratory  
15 arrest).

16 Intraventricular access is performed through a right frontal of the brain. Bleeding can  
17 occur along the trajectory at each level: sub cutaneous hematoma or epidural hematoma are  
18 rare. Subdural hematoma can occur by direct bleeding or an intracranial hypotension  
19 secondary to a CSF loss, intraparenchymal hematoma can be asymptomatic but may, if  
20 extended, lead to motor or cognitive impairment. Intraventricular bleeding may be  
21 responsible for headaches and sometimes secondary hydrocephalus.

22

### 23 Linked to the treatment

24 Gene therapy using viral vectors is mainly hampered by immunogenicity<sup>121-125</sup> particularly  
25 with AAV. Indeed, many people have already been infected by wild-type AAV once in their  
26 life, inducing anti-capsid neutralizing antibodies (NAbs) spread among various serotypes<sup>126-129</sup>.  
27 Moreover, cross-reactive immunologic material (CRIM) status is also important to predict  
28 clinical response. CRIM-negative patients with null mutations or out of frame stop codons are  
29 completely unable to produce protein [that has to be supplied/involved in their disease] and  
30 are therefore more predisposed to develop an anti-transgene response<sup>130,131</sup>. Such host  
31 immune responses, particularly happening when intravenous and intramuscular injections are  
32 performed, significantly impair delivery of the therapeutic protein and be possibly deleterious

1 for patients<sup>132–134</sup>. Delivery of AAV vectors directly into the brain induce low or absent anti-  
2 capsid or anti-transgene NAb titers in serum<sup>119,135–138</sup>. Thus, it must be considered for patient  
3 inclusion criterias and study design in clinical trials. Conventional strategies to prevent  
4 immunogenicity include corticosteroids or immunosuppressive drugs. Corticosteroids (e.g.  
5 methylprednisolone, prednisone) and immunosuppressive drugs (e.g. sirolimus, tacrolimus,  
6 rituximab, bortezomib, mycophenolate, cyclosporine) are administered post-injection and  
7 eventually in pretreatment in several clinical trials<sup>41,139,140</sup>, though their effects are  
8 controversial<sup>141,142</sup>. Other approaches are emerging such as plasmapheresis<sup>141,142</sup>, editing AAV  
9 capsids to eradicate epitopes that induce NAb generation<sup>143</sup>, using tolerogenic  
10 nanoparticles<sup>144,145</sup>, and the incorporation in the transgene of microRNAs (miR) target  
11 sequences integrated in the expression cassette that specifically repress translation in  
12 antigen-presenting cells (APCs)<sup>146,147</sup> or oligonucleotide sequences that inhibit toll-like  
13 receptor 9 (TLR9) activation (in development by George Church’s laboratory, Harvard Medical  
14 School, patent WO2017214378A1).

15

## 16 ***Future development and perspectives***

### 17 *New AAV serotypes with broad CNS transduction after IV delivery*

18 Over the last decade, significant efforts have been expended in updating the natural  
19 repertoire of viral vectors as well as engineering new serotypes<sup>148</sup>. Using the Cre  
20 recombination-based AAV targeted evolution (CREATE) technique, new AAV variants have  
21 been isolated, some able to homogenously transduce the central nervous system, especially  
22 neurons and astrocytes, after intravenous injection in mice<sup>149,150</sup>, and potentially in NHP  
23 although clear evidence of efficacy remain to be demonstrated. Improved CNS transduction is  
24 linked to Ly6 which is not expressed in all mouse lines and not in NHP<sup>151,152</sup>. Indeed a major  
25 challenge is to identify capsids that will be able to efficiently pass the BBB and in mice, NHPs  
26 and human subjects. In addition, the selected capsids should be compatible for large scale  
27 production.

28

### 29 *Blood Brain barrier opening as a solution to enhance CNS targeting*

30 Temporary disruption of the BBB might help delivery in the brain parenchyma. Osmotic  
31 disruption of the BBB with intra-arterial injection of mannitol has been widely studied and  
32 allows for delivery of a variety of drugs and agents into the CNS, including viral vectors<sup>153</sup>.

1 However, this technique induces a diffuse opening of the BBB, precluding for targeted delivery  
2 of drugs and is potentially associated with significant neurological side effects.

3 Ultrasound-induced transitory disruption of the BBB is another technique that has gained  
4 increasing interest since Hynynen et al. demonstrated that the IV injection of preformed gas  
5 bubbles prior to low intensity pulsed ultrasound (US) sonications allowed for a reduction of  
6 the acoustic pressure necessary to safely open the BBB in rabbits<sup>154</sup>. The interaction between  
7 US and injected microbubbles is essential for opening of the BBB, and mechanisms of BBB  
8 disruption may include transcytosis, cell fenestrations, and opening of tight junctions<sup>155</sup>. US-  
9 induced BBB disruption can be monitored with MRI, as a contrast enhancement in T1-  
10 weighted sequences after gadolinium injection<sup>154</sup> and is limited to the US beam<sup>156</sup>.

11 The safety of the technic has been assessed through pre-clinical studies. With optimized  
12 parameters, histological side effects are limited to red blood cell extravasation and petechial  
13 bleeding<sup>157</sup> after both single or multiple US sessions<sup>158</sup>. BBB disruption may induce a transitory  
14 sterile inflammatory response<sup>159</sup>. Recent studies have confirmed that the technic was clinically  
15 well-tolerated in non-human primates<sup>160</sup>.

16 This technic was used to deliver an AAV1/2 viral vector in a targeted manner to the striatum  
17 of rats. Transduction observed was mainly restricted to neurons and stable during more than  
18 one year<sup>161</sup>. Two main approaches have been developed in order to bypass the skull interface  
19 that induces attenuation and distortion of the ultrasound beam. In one case, InSightec (Haifa,  
20 Israel) developed a 512-element phased-array transducer, the ExAblate® 4000 system, that  
21 allows a transcranial and noninvasive opening of the BBB (McDannold et al. 2010). On-going  
22 clinical trials are currently evaluating the safety of the ExAblate® system for drug delivery after  
23 BBB disruption (NCT02343991, NCT02253212). In another case, CarThera SAS (Paris, France)  
24 designed an implantable device, the SonoCloud® device, which can be plugged into the skull,  
25 and activated through a transdermal needle <sup>156</sup>. Interim results of the first clinical trial  
26 (SONOCLOUD, NCT02253212) evaluating the safety of this system in adult patients treated for  
27 recurrent glioblastoma with systemic carboplatin have shown no dose limiting toxicities and  
28 no treatment-related serious adverse events<sup>162</sup>. A phase I trial (SONOKID) assessing the safety  
29 of repeated BBB disruptions by the SonoCloud® device in association with intravenous  
30 chemotherapy in recurrent supra-tentorial malignant primitive tumors in the pediatric  
31 population should begin during 2020<sup>163</sup>. More recent studies have been reported with  
32 percutaneous ultrasound but with no additional value<sup>164</sup>.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32

Encapsulated cells and Optogenetics

Encapsulated cell technology (ECT) eventually combined with optogenetics allows the delivery of treatment in a continuous or in a controlled/discontinuous ways, respectively.

ECT is a concept based on the confinement of the grafted cells within a permeable device.

ECT has already been shown to be well tolerated in large animals such as dogs for the treatment of intervertebral disc degeneration<sup>165</sup>, in pigs<sup>166</sup> and NHPs<sup>167</sup> for Alzheimer’s disease. Moreover, ECT has already been translated to clinical studies where the safety, feasibility, and tolerability of procedure has been shown e.g the delivery of neurotrophic factor in disorders of eye (<sup>168–170</sup>; clinicalTrial.gov NCT00447980, NCT00447993, NCT02228304, NCT00447954), in Alzheimer’s disease (<sup>171</sup>; NCT01163825), in Huntington’s disease<sup>172,173</sup> and in amyotrophic lateral sclerosis<sup>174</sup>. Moreover delivery of anti-amyloid immunotherapy by ECT is described in AD patients<sup>175,176</sup>. Thus, ECT provides an innovative approach for the local and systemic delivery of a recombinant protein in the CNS.

The optogenetics approach uses optical methods to modulate the cellular expression of molecules, which are activated by irradiation with light energy by genetic engineering to control/regulate cellular function or intracellular signal transduction<sup>177</sup>. One of the challenges of optogenetics is its translatability to the clinic. Many improvements in optogenetic technologies in NHPs have been performed to exert precise control of specific cells or brain regions at the millisecond timescale and to reliably transduce cells and readout the optically induced neural modulation<sup>178,179</sup>. A new optogenetic approach has been described by Ruiz et al., 2013 in which the native dura is replaced with optically transparent artificial dura allowing visual monitoring of the expression of the optogenetic agent over time.

The first optogenetic study of NHP was performed in 2009<sup>180</sup> and followed by numerous studies performed to study the link between brain function and behavior using optogenetic stimulation<sup>181,182</sup>. None of the optogenetic studies allowing the delivery of treatment was performed in NPH. However, many applications of optogenetics in CNS diseases (Stroke, Epilepsy, MS, AD, PD) were described by Ordaz et al., 2017. One of the major obstacles to widely use optogenetic tools in patients remains the delivery to the brain. For this reason, it is essential to reduce brain tissue damage inflicted by probe penetrations and light-induced heating for optogenetic procedures. Once these problems are overcome, optogenetics can be an advantageous tool to treat neurological diseases providing an alternative treatment with

1 less side effects than current therapies<sup>183</sup>. The first patient dosed with optogenetics was  
2 treated for retinitis pigmentosa in a clinical trial conducted by RetroSense Therapeutic in 2016.  
3 More recently, one Phase I/II clinical trial of optogenetics for vision restoration is registered  
4 (NCT02556736, sponsor Allergan; NCT03326336, sponsor GenSight), but no results have been  
5 published to date.

### 6 7 Hematopoietic Stem cell gene therapy to treat CNS diseases

8 Hematopoietic stem cell transplantation (HSCT) is the best example of stem-cell therapy and  
9 is currently an established treatment for several neurologically devastating inherited  
10 metabolic diseases, including adrenoleukodystrophy and LSDs<sup>21,22</sup>. In LSDs, donor-derived  
11 microglia cells of myeloid origin are thought to be the source of enzyme after HSCT, cross-  
12 correcting the metabolic defect in affected host cells<sup>184</sup>. In addition, engrafted donor-derived  
13 cells may potentially help in reducing accumulated toxic substrates in the brain. Of  
14 importance, there is evidence that stem cells are not only replacing dying cells, but are also  
15 regulating inflammation and immune responses and have pro-neurogenic effects<sup>185</sup>.

16 Numerous studies support the notion of using stem cells as a treatment for inherited diseases  
17 like LSDs<sup>184</sup>, HD, but also for complex diseases like AD, PD, ALS<sup>186,187</sup>. Further pre-clinical and  
18 clinical studies are needed to ensure the safety and efficacy of these treatment options<sup>187</sup>.

### 19 20 **Conclusion**

21 The recent beneficial results demonstrated in phase I-II studies in human patients together  
22 with improved vector technology have placed gene therapy for CNS diseases in a new  
23 development paradigm. These approaches are no longer restricted to rare genetic diseases,  
24 but are being applied to common disease indications and pathways significantly expanding  
25 the scope of gene therapy for CNS indications. This expansion requires simplifying delivery  
26 protocols and anticipating the increasing need of vector production, particularly for IV  
27 targeting. Treating an increasing number of patients requires standardized delivery protocols  
28 suitable for adaptation in multiple centers around the world. Further, manufacturability is a  
29 central component in expanding the GT field; not only the production of high quality and high  
30 quantity of vectors to meet future clinical demand, but also the cost and our capacity to make  
31 new gene therapy products accessible to all patients.

## References

1. Daneman R, Prat A. The Blood–Brain Barrier. *Cold Spring Harb Perspect Biol*;7 . Epub ahead of print 2015. DOI: 10.1101/CSHPERSPECT.A020412.
2. Zlokovic B V. The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders. *Neuron* 2008;57:178–201.
3. Hocquemiller M, Giersch L, Audrain M, et al. Adeno-Associated Virus-Based Gene Therapy for CNS Diseases. *Hum Gene Ther* 2016;27:478–96.
4. Tărlungeanu DC, Novarino G. Genomics in neurodevelopmental disorders: an avenue to personalized medicine. *Exp Mol Med* 2018;50:100.
5. Gray SJ. Gene therapy and neurodevelopmental disorders. *Neuropharmacology* 2013;68:136–142.
6. Drew L. Gene therapy targets epilepsy. *Nature* 2018;564:S10–S11.
7. Kwiatkowska A, Nandhu MS, Behera P, et al. Strategies in gene therapy for glioblastoma. *Cancers (Basel)* 2013;5:1271–305.
8. Guedon J-MG, Wu S, Zheng X, et al. Current gene therapy using viral vectors for chronic pain. *Mol Pain* 2015;11:27.
9. Tardieu M, Zérah M, Husson B, et al. Intracerebral Administration of Adeno-Associated Viral Vector Serotype rh.10 Carrying Human *SGSH* and *SUMF1* cDNAs in Children with Mucopolysaccharidosis Type IIIA Disease: Results of a Phase I/II Trial. *Hum Gene Ther* 2014;25:506–516.
10. Tardieu M, Zérah M, Gougeon M-L, et al. Intracerebral gene therapy in children with mucopolysaccharidosis type IIIB syndrome: an uncontrolled phase 1/2 clinical trial. *Lancet Neurol* 2017;16:712–720.
11. Zerah M, Piguet F, Colle M-A, et al. Intracerebral Gene Therapy Using AAVrh.10-hARSA Recombinant Vector to Treat Patients with Early-Onset Forms of Metachromatic Leukodystrophy: Preclinical Feasibility and Safety Assessments in Nonhuman Primates. *Hum Gene Ther Clin Dev* 2015;26:113–124.
12. Mendell JR, Al-Zaidy S, Shell R, et al. Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy. *N Engl J Med* 2017;377:1713–1722.
13. Meyer K, Ferraiuolo L, Schmelzer L, et al. Improving Single Injection CSF Delivery of AAV9-mediated Gene Therapy for SMA: A Dose–response Study in Mice and Nonhuman Primates. *Mol Ther* 2015;23:477–487.
14. Bestor TH. Gene silencing as a threat to the success of gene therapy. *J Clin Invest* 2000;105:409–11.
15. Rindt H, Yen P-F, Thebeau CN, et al. Replacement of huntingtin exon 1 by trans-splicing. *Cell Mol Life Sci* 2012;69:4191–4204.
16. Bouscicault L, Alves S, Lamazière A, et al. CYP46A1, the rate-limiting enzyme for cholesterol degradation, is neuroprotective in Huntington’s disease. *Brain* 2016;139:953–70.
17. Burlot M-A, Braudeau J, Michaelsen-Preusse K, et al. Cholesterol 24-hydroxylase defect is implicated in memory impairments associated with Alzheimer-like Tau pathology. *Hum Mol Genet* 2015;24:5965–5976.
18. Rose C, Dorard E, Audrain M, et al. Transient increase in sAPP $\alpha$  secretion in response to A $\beta$ 1-42 oligomers: an attempt of neuronal self-defense? *Neurobiol Aging* 2018;61:23–35.
19. Audrain M, Souchet B, Alves S, et al.  $\beta$ APP Processing Drives Gradual Tau Pathology in an Age-Dependent Amyloid Rat Model of Alzheimer’s Disease. *Cereb Cortex* 2017;1–18.
20. Hulou MM, Cho C-F, Chiocca EA, et al. Experimental therapies. In: *Handbook of clinical neurology*; pp. 183–197.
21. Sessa M, Lorioli L, Fumagalli F, et al. Lentiviral haemopoietic stem-cell gene therapy in early-onset metachromatic leukodystrophy: an ad-hoc analysis of a non-randomised, open-label, phase 1/2 trial. *Lancet* 2016;388:476–487.
22. Eichler F, Duncan C, Musolino PL, et al. Hematopoietic Stem-Cell Gene Therapy for Cerebral Adrenoleukodystrophy. *N Engl J Med* 2017;377:1630–1638.

- 1 23. Piguet F, Alves S, Cartier N. Clinical Gene Therapy for Neurodegenerative Diseases: Past,  
2 Present, and Future. *Human Gene Therapy* 2017;28:988–1003.
- 3 24. Gao G, Vandenberghe L, Wilson J. New Recombinant Serotypes of AAV Vectors. *Curr Gene*  
4 *Ther* 2005;5:285–297.
- 5 25. Srivastava A, Carter BJ. AAV Infection: Protection from Cancer. *Hum Gene Ther* 2017;28:323–  
6 327.
- 7 26. Nault JC, Mami I, La Bella T, et al. Wild-type AAV insertions in hepatocellular carcinoma do not  
8 inform debate over genotoxicity risk of vectorized AAV. *Molecular Therapy* 2016;24:660–661.
- 9 27. Hastie E, Samulski RJ. Adeno-Associated Virus at 50: A Golden Anniversary of Discovery,  
10 Research, and Gene Therapy Success - A Personal Perspective. *Human Gene Therapy*  
11 2015;26:257–265.
- 12 28. Ginn SL, Amaya AK, Alexander IE, et al. Gene therapy clinical trials worldwide to 2017: An  
13 update. *Journal of Gene Medicine* 2018;20:e3015.
- 14 29. Pillay S, Carette JE. Host determinants of adeno-associated viral vector entry. *Current Opinion*  
15 *in Virology* 2017;24:124–131.
- 16 30. Castle MJ, Turunen HT, Vandenberghe LH, et al. Controlling AAV tropism in the nervous  
17 system with natural and engineered capsids. In: *Methods in Molecular Biology*. Humana Press  
18 Inc.; pp. 133–149.
- 19 31. Vandenberghe LH, Wilson JM, Gao G. Tailoring the AAV vector capsid for gene therapy. *Gene*  
20 *Therapy* 2009;16:311–319.
- 21 32. Auricchio A. Exchange of surface proteins impacts on viral vector cellular specificity and  
22 transduction characteristics: the retina as a model. *Hum Mol Genet* 2001;10:3075–3081.
- 23 33. Hadaczek P, Stanek L, Ciesielska A, et al. Widespread AAV1- and AAV2-mediated transgene  
24 expression in the nonhuman primate brain: implications for Huntington’s disease. *Mol Ther -*  
25 *Methods Clin Dev* 2016;3:16037.
- 26 34. Bartus RT, Baumann TL, Siffert J, et al. Safety/feasibility of targeting the substantia nigra with  
27 AAV2-neurturin in Parkinson patients. *Neurology* 2013;80:1698–701.
- 28 35. Chien Y-H, Lee N-C, Tseng S-H, et al. Efficacy and safety of AAV2 gene therapy in children with  
29 aromatic L-amino acid decarboxylase deficiency: an open-label, phase 1/2 trial. *Lancet Child*  
30 *Adolesc Heal* 2017;1:265–273.
- 31 36. Mittermeyer G, Christine CW, Rosenbluth KH, et al. Long-Term Evaluation of a Phase 1 Study  
32 of AADC Gene Therapy for Parkinson’s Disease. *Hum Gene Ther* 2012;23:377–381.
- 33 37. Colle M-A, Piguet F, Bertrand L, et al. Efficient intracerebral delivery of AAV5 vector encoding  
34 human ARSA in non-human primate. *Hum Mol Genet* 2010;19:147–158.
- 35 38. Tardieu M, Zerah M, Husson B, et al. Intracerebral Administration of Adeno-Associated Viral  
36 Vector Serotype rh.10 Carrying Human SGSH and SUMF1 cDNAs in Children with  
37 Mucopolysaccharidosis Type IIIA Disease: Results of a Phase I/II Trial . *Hum Gene Ther* . Epub  
38 ahead of print 2014. DOI: 10.1089/hum.2013.238.
- 39 39. Foust KD, Wang X, McGovern VL, et al. Rescue of the spinal muscular atrophy phenotype in a  
40 mouse model by early postnatal delivery of SMN. *Nat Biotechnol* 2010;28:271–4.
- 41 40. Murrey DA, Naughton BJ, Duncan FJ, et al. Feasibility and Safety of Systemic rAAV9-h *NAGLU*  
42 Delivery for Treating Mucopolysaccharidosis IIIB: Toxicology, Biodistribution, and  
43 Immunological Assessments in Primates. *Hum Gene Ther Clin Dev* 2014;25:72–84.
- 44 41. Mendell JR, Al-Zaidy S, Shell R, et al. Single-Dose Gene-Replacement Therapy for Spinal  
45 Muscular Atrophy. *N Engl J Med* 2017;377:1713–1722.
- 46 42. Lipinski DM, Reid CA, Boye SL, et al. AAV Vectors II 314. Systemic Vascular Transduction  
47 Following Intravenous Injection of Capsid Mutant Adeno-Associated Virus. 2015 . Epub ahead  
48 of print 2015. DOI: 10.1038/mt.2015.74.
- 49 43. Gessler DJ, Tai PWL, Li J, et al. Intravenous infusion of AAV for widespread gene delivery to  
50 the nervous system. In: *Methods in Molecular Biology*. Humana Press Inc.; pp. 143–163.
- 51 44. Deverman BE, Pravdo PL, Simpson BP, et al. Cre-dependent selection yields AAV variants for  
52 widespread gene transfer to the adult brain. *Nat Biotechnol* 2016;34:204–209.

- 1 45. Hordeaux J, Wang Q, Katz N, et al. The Neurotropic Properties of AAV-PHP.B Are Limited to  
2 C57BL/6J Mice. *Mol Ther* 2018;26:664–668.
- 3 46. Zufferey R, Dull T, Mandel RJ, et al. Self-Inactivating Lentivirus Vector for Safe and Efficient In  
4 Vivo Gene Delivery. *J Virol* 1998;72:9873–9880.
- 5 47. Escors D, Breckpot K. Lentiviral vectors in gene therapy: Their current status and future  
6 potential. *Archivum Immunologiae et Therapiae Experimentalis* 2010;58:107–119.
- 7 48. Delzor A, Aurélie D, Escartin C, et al. Lentiviral vectors: a powerful tool to target astrocytes in  
8 vivo. *Curr Drug Targets* 2013;14:1336–46.
- 9 49. Hastie E, Cataldi M, Marriott I, et al. Understanding and altering cell tropism of vesicular  
10 stomatitis virus. *Virus Research* 2013;176:16–32.
- 11 50. Carlotti F, Bazuine M, Kekarainen T, et al. Lentiviral vectors efficiently transduce quiescent  
12 mature 3T3-L1 adipocytes. *Mol Ther* 2004;9:209–217.
- 13 51. Geng X, Doitsh G, Yang Z, et al. Efficient delivery of lentiviral vectors into resting human CD4 T  
14 cells. *Gene Ther* 2014;21:444–449.
- 15 52. Jakobsson J, Lundberg C. Lentiviral vectors for use in the central nervous system. *Molecular  
16 Therapy* 2006;13:484–493.
- 17 53. Cartier N, Hacein-Bey-Abina S, Bartholomae CC, et al. Hematopoietic stem cell gene therapy  
18 with a lentiviral vector in X-linked adrenoleukodystrophy. *Science* 2009;326:818–23.
- 19 54. Staal FJT, Aiuti A, Cavazzana M. Autologous Stem-Cell-Based Gene Therapy for Inherited  
20 Disorders: State of the Art and Perspectives. *Frontiers in Pediatrics* 2019;7:443.
- 21 55. Stein S, Ott MG, Schultze-Strasser S, et al. Genomic instability and myelodysplasia with  
22 monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous  
23 disease. *Nat Med* 2010;16:198–204.
- 24 56. Zychlinski D, Schambach A, Modlich U, et al. Physiological promoters reduce the genotoxic risk  
25 of integrating gene vectors. *Mol Ther* 2008;16:718–725.
- 26 57. Poletti V, Charrier S, Corre G, et al. Preclinical Development of a Lentiviral Vector for Gene  
27 Therapy of X-Linked Severe Combined Immunodeficiency. *Mol Ther - Methods Clin Dev*  
28 2018;9:257–269.
- 29 58. Doi K, Takeuchi Y. Gene therapy using retrovirus vectors: vector development and biosafety at  
30 clinical trials. *Virus* 2015;65:27–36.
- 31 59. Rothe M, Modlich U, Schambach A. Biosafety Challenges for Use of Lentiviral Vectors in Gene  
32 Therapy. *Curr Gene Ther* 2014;13:453–468.
- 33 60. Katsouri L, Lim YM, Blondrath K, et al. PPAR $\gamma$ -coactivator-1 $\alpha$  gene transfer reduces neuronal  
34 loss and amyloid- $\beta$  generation by reducing  $\beta$ -secretase in an Alzheimer's disease model. *Proc  
35 Natl Acad Sci U S A* 2016;113:12292–12297.
- 36 61. Palfi S, Gurruchaga JM, Lepetit H, et al. Long-Term Follow-Up of a Phase I/II Study of ProSavin,  
37 a Lentiviral Vector Gene Therapy for Parkinson's Disease. *Hum Gene Ther Clin Dev*  
38 2018;29:148–155.
- 39 62. Azzouz M, Martin-Rendon E, Barber RD, et al. Multicistronic lentiviral vector-mediated striatal  
40 gene transfer of aromatic L-amino acid decarboxylase, tyrosine hydroxylase, and GTP  
41 cyclohydrolase I induces sustained transgene expression, dopamine production, and  
42 functional improvement in a rat model of Parkinson's disease. *J Neurosci* 2002;22:10302–  
43 10312.
- 44 63. Blagbrough IS, Zara C. Animal Models for Target Diseases in Gene Therapy — using DNA and  
45 siRNA Delivery Strategies. *Pharm Res* 2009;26:1–18.
- 46 64. Hattori N, Sato S. Animal models of Parkinson's disease: similarities and differences between  
47 the disease and models. *Neuropathology* 2007;27:479–83.
- 48 65. Lasbleiz C, Mestre-Francés N, Devau G, et al. Combining Gene Transfer and Nonhuman  
49 Primates to Better Understand and Treat Parkinson's Disease. *Front Mol Neurosci* 2019;12:10.
- 50 66. Gopinath C, Nathar TJ, Ghosh A, et al. Contemporary Animal Models For Human Gene  
51 Therapy Applications. *Curr Gene Ther* 2015;15:531–40.
- 52 67. Dawson T, Mandir A, Lee M. Animal models of PD: pieces of the same puzzle? *Neuron*

- 1 2002;35:219–22.
- 2 68. Wolfe JH. Gene therapy in large animal models of human genetic diseases. Introduction. ILAR  
3 J 2009;50:107–11.
- 4 69. Bankiewicz KS, Sudhakar V, Samaranch L, et al. AAV viral vector delivery to the brain by shape-  
5 conforming MR-guided infusions. J Control Release 2016;240:434–442.
- 6 70. Samaranch L, Salegio EA, San Sebastian W, et al. Strong cortical and spinal cord transduction  
7 after AAV7 and AAV9 delivery into the cerebrospinal fluid of nonhuman primates. Hum Gene  
8 Ther 2013;24:526–32.
- 9 71. Salegio EA, Samaranch L, Kells AP, et al. Axonal transport of adeno-associated viral vectors is  
10 serotype-dependent. Gene Ther 2013;20:348–352.
- 11 72. Salegio EA, Samaranch L, Kells AP, et al. Axonal transport of adeno-associated viral vectors is  
12 serotype-dependent. Gene Ther 2013;20:348–352.
- 13 73. Kells AP, Forsayeth J, Bankiewicz KS. Glial-derived neurotrophic factor gene transfer for  
14 Parkinson’s disease: anterograde distribution of AAV2 vectors in the primate brain. Neurobiol  
15 Dis 2012;48:228–35.
- 16 74. Ciesielska A, Mittermeyer G, Hadaczek P, et al. Anterograde Axonal Transport of AAV2-GDNF  
17 in Rat Basal Ganglia. Mol Ther 2011;19:922–927.
- 18 75. Green F, Samaranch L, Zhang HS, et al. Axonal transport of AAV9 in nonhuman primate brain.  
19 Gene Ther 2016;23:520–6.
- 20 76. Evers MM, Miniarikova J, Juhas S, et al. AAV5-miHTT Gene Therapy Demonstrates Broad  
21 Distribution and Strong Human Mutant Huntingtin Lowering in a Huntington’s Disease Minipig  
22 Model. Mol Ther . Epub ahead of print 2018. DOI: 10.1016/j.ymthe.2018.06.021.
- 23 77. Hocquemiller M, Hemsley KM, Douglass ML, et al. AAVrh10 Vector Corrects Disease Pathology  
24 in MPS IIIA Mice and Achieves Widespread Distribution of SGSH in Large Animal Brains. Mol  
25 Ther - Methods Clin Dev 2020;17:174–187.
- 26 78. Kordower JH, Emborg ME, Bloch J, et al. Neurodegeneration Prevented by Lentiviral Vector  
27 Delivery of GDNF in Primate Models of Parkinson’s Disease. Science (80- ) 2000;290:767–773.
- 28 79. Jarraya B, Boulet S, Scott Ralph G, et al. Dopamine Gene Therapy for Parkinson’s Disease in a  
29 Nonhuman Primate Without Associated Dyskinesia. Sci Transl Med 2009;1:2ra4-2ra4.
- 30 80. Linterman KS, Palmer DN, Kay GW, et al. Lentiviral-mediated gene transfer to the sheep brain:  
31 implications for gene therapy in Batten disease. Hum Gene Ther 2011;22:1011–20.
- 32 81. Duque SI, Arnold WD, Odermatt P, et al. A large animal model of spinal muscular atrophy and  
33 correction of phenotype. Ann Neurol 2015;77:399–414.
- 34 82. Katz ML, Tecedor L, Chen Y, et al. AAV gene transfer delays disease onset in a TPP1-deficient  
35 canine model of the late infantile form of Batten disease. Sci Transl Med 2015;7:313ra180-  
36 313ra180.
- 37 83. Samaranch L, Salegio EA, San Sebastian W, et al. Adeno-associated virus serotype 9  
38 transduction in the central nervous system of nonhuman primates. Hum Gene Ther  
39 2012;23:382–9.
- 40 84. Samaranch L, Sebastian WS, Kells AP, et al. AAV9-mediated expression of a non-self protein in  
41 nonhuman primate central nervous system triggers widespread neuroinflammation driven by  
42 antigen-presenting cell transduction. Mol Ther 2014;22:329–337.
- 43 85. Rosenberg JB, Sondhi D, Rubin DG, et al. Comparative Efficacy and Safety of Multiple Routes  
44 of Direct CNS Administration of Adeno-Associated Virus Gene Transfer Vector Serotype rh.10  
45 Expressing the Human Arylsulfatase A cDNA to Nonhuman Primates. Hum Gene Ther Clin Dev  
46 2014;25:164–177.
- 47 86. Rosenberg JB, Kaplitt MG, De BP, et al. AAVrh.10-Mediated APOE2 Central Nervous System  
48 Gene Therapy for APOE4-Associated Alzheimer’s Disease. Hum Gene Ther Clin Dev  
49 2018;29:24–47.
- 50 87. Passini MA, Bu J, Richards AM, et al. Translational Fidelity of Intrathecal Delivery of Self-  
51 Complementary AAV9–Survival Motor Neuron 1 for Spinal Muscular Atrophy. Hum Gene Ther  
52 2014;25:619–630.

- 1 88. Hinderer C, Bell P, Vite CH, et al. Widespread gene transfer in the central nervous system of  
2 cynomolgus macaques following delivery of AAV9 into the cisterna magna. *Mol Ther -*  
3 *Methods Clin Dev* 2014;1:14051.
- 4 89. Haurigot V, Marcó S, Ribera A, et al. Whole body correction of mucopolysaccharidosis IIIA by  
5 intracerebrospinal fluid gene therapy. *J Clin Invest* 2013;123:3254–3271.
- 6 90. Gray SJ, Matagne V, Bachaboina L, et al. Preclinical differences of intravascular AAV9 delivery  
7 to neurons and glia: a comparative study of adult mice and nonhuman primates. *Mol Ther*  
8 2011;19:1058–69.
- 9 91. Duque S, Joussemet B, Riviere C, et al. Intravenous Administration of Self-complementary  
10 AAV9 Enables Transgene Delivery to Adult Motor Neurons. *Mol Ther* 2009;17:1187–1196.
- 11 92. Bucher T, Dubreil L, Colle M-A, et al. Intracisternal delivery of AAV9 results in oligodendrocyte  
12 and motor neuron transduction in the whole central nervous system of cats. *Gene Ther*  
13 2014;21:522–528.
- 14 93. Gurda BL, De Guilhem De Lataillade A, Bell P, et al. Evaluation of AAV-mediated Gene Therapy  
15 for Central Nervous System Disease in Canine Mucopolysaccharidosis VII. *Mol Ther*  
16 2016;24:206–216.
- 17 94. Hinderer C, Bell P, Louboutin J-P, et al. Neonatal Systemic AAV Induces Tolerance to CNS Gene  
18 Therapy in MPS I Dogs and Nonhuman Primates. *Mol Ther* 2015;23:1298–1307.
- 19 95. Borel F, Gernoux G, Cardozo B, et al. Therapeutic rAAVrh10 Mediated *SOD1* Silencing in Adult  
20 *SOD1*<sup>G93A</sup> Mice and Nonhuman Primates. *Hum Gene Ther* 2016;27:19–31.
- 21 96. Bevan AK, Duque S, Foust KD, et al. Systemic Gene Delivery in Large Species for Targeting  
22 Spinal Cord, Brain, and Peripheral Tissues for Pediatric Disorders. *Mol Ther* 2011;19:1971–  
23 1980.
- 24 97. Yang B, Li S, Wang H, et al. Global CNS transduction of adult mice by intravenously delivered  
25 rAAVrh.8 and rAAVrh.10 and nonhuman primates by rAAVrh.10. In: *Molecular Therapy.*  
26 Nature Publishing Group; pp. 1299–1309.
- 27 98. Borel F, Gernoux G, Sun H, et al. Safe and effective superoxide dismutase 1 silencing using  
28 artificial microRNA in macaques. *Sci Transl Med* 2018;10:eaau6414.
- 29 99. Hinderer C, Bell P, Katz N, et al. Evaluation of Intrathecal Routes of Administration for Adeno-  
30 Associated Viral Vectors in Large Animals. *Hum Gene Ther* 2018;29:15–24.
- 31 100. Bravo-Hernandez M, Tadokoro T, Navarro MR, et al. Spinal subpial delivery of AAV9 enables  
32 widespread gene silencing and blocks motoneuron degeneration in ALS. *Nat Med*  
33 2020;26:118–130.
- 34 101. Tadokoro T, Miyanojara A, Navarro M, et al. Subpial adeno-associated virus 9 (AAV9) vector  
35 delivery in adult mice. *J Vis Exp*;2017 . Epub ahead of print July 13, 2017. DOI: 10.3791/55770.
- 36 102. Wolf DA, Banerjee S, Hackett PB, et al. Gene therapy for neurologic manifestations of  
37 mucopolysaccharidoses. *Expert Opin Drug Deliv* 2015;12:283–296.
- 38 103. Hordeaux J, Dubreil L, Robveille C, et al. Long-term neurologic and cardiac correction by  
39 intrathecal gene therapy in Pompe disease. *Acta Neuropathol Commun* 2017;5:66.
- 40 104. Hordeaux J, Hinderer C, Goode T, et al. Toxicology Study of Intra-Cisterna Magna Adeno-  
41 Associated Virus 9 Expressing Human Alpha-L-Iduronidase in Rhesus Macaques. *Mol Ther -*  
42 *Methods Clin Dev* 2018;10:79–88.
- 43 105. Kim I, Paek S, Nelson BD, et al. Implementation of a chronic unilateral intraparenchymal drug  
44 delivery system in a swine model. *J Neurosci Methods* 2014;227:29–34.
- 45 106. Brady ML, Raghavan R, Alexander A, et al. Pathways of Infusate Loss during Convection-  
46 Enhanced Delivery into the Putamen Nucleus. *Stereotact Funct Neurosurg* 2013;91:69–78.
- 47 107. Belova E, Shaffer CL, Trapa PE. Insights from mathematical modeling for convection-enhanced  
48 intraputamenal delivery of GDNF. *Med Biol Eng Comput* 2017;55:2069–2077.
- 49 108. Vazquez LC, Hagel E, Willenberg BJ, et al. Polymer-coated cannulas for the reduction of  
50 backflow during intraparenchymal infusions. *J Mater Sci Mater Med* 2012;23:2037–2046.
- 51 109. Ung TH, Malone H, Canoll P, et al. Convection-enhanced delivery for glioblastoma: targeted  
52 delivery of antitumor therapeutics. *CNS Oncol* 2015;4:225–34.

- 1 110. Lueshen E, Tangen K, Mehta AI, et al. Backflow-free catheters for efficient and safe  
2 convection-enhanced delivery of therapeutics. *Med Eng Phys* 2017;45:15–24.
- 3 111. Krauze MT, Saito R, Noble C, et al. Reflux-free cannula for convection-enhanced high-speed  
4 delivery of therapeutic agents. *J Neurosurg* 2005;103:923–9.
- 5 112. Lewis O, Woolley M, Johnson D, et al. Chronic, intermittent convection-enhanced delivery  
6 devices. *J Neurosci Methods* 2016;259:47–56.
- 7 113. Debinski W, Tatter SB. Convection-enhanced delivery for the treatment of brain tumors.  
8 *Expert Rev Neurother* 2009;9:1519–1527.
- 9 114. Fan X, Nelson BD, Ai Y, et al. Continuous intraputamenal convection-enhanced delivery in  
10 adult rhesus macaques. *J Neurosurg* 2015;123:1569–1577.
- 11 115. Debinski W, Tatter SB. Convection-enhanced delivery for the treatment of brain tumors.  
12 *Expert Rev Neurother* 2009;9:1519–27.
- 13 116. Lewis O, Woolley M, Johnson D, et al. Chronic, intermittent convection-enhanced delivery  
14 devices. *Journal of Neuroscience Methods* 2016;259:47–56.
- 15 117. Bienemann A, White E, Woolley M, et al. The development of an implantable catheter system  
16 for chronic or intermittent convection-enhanced delivery. *J Neurosci Methods* 2012;203:284–  
17 291.
- 18 118. Vogelbaum MA, Brewer C, Barnett GH, et al. First-in-human evaluation of the Cleveland  
19 Multiport Catheter for convection-enhanced delivery of topotecan in recurrent high-grade  
20 glioma: results of pilot trial 1. *J Neurosurg* 2019;130:476–485.
- 21 119. Christine CW, Bankiewicz KS, Van Laar AD, et al. Magnetic resonance imaging–guided phase 1  
22 trial of putaminal AADC gene therapy for Parkinson’s disease. *Ann Neurol* 2019;85:704–714.
- 23 120. Bankiewicz KS, Sudhakar V, Samaranch L, et al. AAV viral vector delivery to the brain by shape-  
24 conforming MR-guided infusions. *J Control Release* 2016;240:434–442.
- 25 121. Nayak S, Herzog RW. Progress and prospects: immune responses to viral vectors. *Gene Ther*  
26 2010;17:295–304.
- 27 122. Mingozzi F, Maus M V, Hui DJ, et al. CD8+ T-cell responses to adeno-associated virus capsid in  
28 humans. *Nat Med* 2007;13:419–422.
- 29 123. Basner-Tschakarjan E, Mingozzi F. Cell-Mediated Immunity to AAV Vectors, Evolving Concepts  
30 and Potential Solutions. *Front Immunol* 2014;5:350.
- 31 124. Calcedo R, Wilson JM. Humoral Immune Response to AAV. *Front Immunol* 2013;4:341.
- 32 125. Rogers GL, Martino AT, Aslanidi G V., et al. Innate Immune Responses to AAV Vectors. *Front*  
33 *Microbiol* 2011;2:194.
- 34 126. Calcedo R, Vandenberghe LH, Gao G, et al. Worldwide Epidemiology of Neutralizing  
35 Antibodies to Adeno-Associated Viruses. *J Infect Dis* 2009;199:381–390.
- 36 127. Veron P, Leborgne C, Monteilhet V, et al. Humoral and cellular capsid-specific immune  
37 responses to adeno-associated virus type 1 in randomized healthy donors. *J Immunol*  
38 2012;188:6418–24.
- 39 128. Boutin S, Monteilhet V, Veron P, et al. Prevalence of Serum IgG and Neutralizing Factors  
40 Against Adeno-Associated Virus (AAV) Types 1, 2, 5, 6, 8, and 9 in the Healthy Population:  
41 Implications for Gene Therapy Using AAV Vectors. *Hum Gene Ther* 2010;21:704–712.
- 42 129. Wang Z, Tapscott SJ, Chamberlain JS, et al. Immunity and AAV-Mediated Gene Therapy for  
43 Muscular Dystrophies in Large Animal Models and Human Trials. *Front Microbiol* 2011;2:201.
- 44 130. Banugaria SG, Prater SN, Ng Y-K, et al. The impact of antibodies on clinical outcomes in  
45 diseases treated with therapeutic protein: lessons learned from infantile Pompe disease.  
46 *Genet Med* 2011;13:729–36.
- 47 131. Berrier KL, Kazi ZB, Prater SN, et al. CRIM-negative infantile Pompe disease: characterization  
48 of immune responses in patients treated with ERT monotherapy. *Genet Med* 2015;17:912–8.
- 49 132. Ferreira V, Petry H, Salmon F. Immune Responses to AAV-Vectors, the Glybera Example from  
50 Bench to Bedside. *Front Immunol*;5 . Epub ahead of print 2014. DOI:  
51 10.3389/fimmu.2014.00082.
- 52 133. Gaudet D, Méthot J, Déry S, et al. Efficacy and long-term safety of alipogene tiparovec

- 1 (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial. *Gene Ther*  
2 2013;20:361–369.
- 3 134. Manno CS, Pierce GF, Arruda VR, et al. Successful transduction of liver in hemophilia by AAV-  
4 Factor IX and limitations imposed by the host immune response. *Nat Med* 2006;12:342–347.
- 5 135. Marks WJ, Bartus RT, Siffert J, et al. Gene delivery of AAV2-neurturin for Parkinson’s disease:  
6 a double-blind, randomised, controlled trial. *Lancet Neurol* 2010;9:1164–1172.
- 7 136. Christine CW, Starr PA, Larson PS, et al. Safety and tolerability of putaminal AADC gene  
8 therapy for Parkinson disease. *Neurology* 2009;73:1662–1669.
- 9 137. McPhee SWJ, Janson CG, Li C, et al. Immune responses to AAV in a phase I study for Canavan  
10 disease. *J Gene Med* 2006;8:577–588.
- 11 138. Kaplitt MG, Feigin A, Tang C, et al. Safety and tolerability of gene therapy with an adeno-  
12 associated virus (AAV) borne GAD gene for Parkinson’s disease: an open label, phase I trial.  
13 *Lancet* 2007;369:2097–2105.
- 14 139. Mingozzi F, Chen Y, Edmonson SC, et al. Prevalence and pharmacological modulation of  
15 humoral immunity to AAV vectors in gene transfer to synovial tissue. *Gene Ther* 2013;20:417–  
16 24.
- 17 140. Corti M, Liberati C, Smith BK, et al. Safety of Intradiaphragmatic Delivery of Adeno-Associated  
18 Virus-Mediated Alpha-Glucosidase (rAAV1-CMV- *hGAA* ) Gene Therapy in Children Affected by  
19 Pompe Disease. *Hum Gene Ther Clin Dev* 2017;28:208–218.
- 20 141. Montenegro-Miranda PS, Bloemendaal L ten, Kunne C, et al. Mycophenolate Mofetil Impairs  
21 Transduction of Single-Stranded Adeno-Associated Viral Vectors. *Hum Gene Ther*  
22 2011;22:605–612.
- 23 142. Unzu C, Hervás-Stubbs S, Sampedro A, et al. Transient and intensive pharmacological  
24 immunosuppression fails to improve AAV-based liver gene transfer in non-human primates. *J*  
25 *Transl Med* 2012;10:122.
- 26 143. Tseng Y-S, Agbandje-McKenna M. Mapping the AAV Capsid Host Antibody Response toward  
27 the Development of Second Generation Gene Delivery Vectors. *Front Immunol* 2014;5:9.
- 28 144. Kishimoto TK, Ferrari JD, LaMothe RA, et al. Improving the efficacy and safety of biologic drugs  
29 with tolerogenic nanoparticles. *Nat Nanotechnol* 2016;11:890–899.
- 30 145. Meliani A, Boisgerault F, Hardet R, et al. Antigen-selective modulation of AAV immunogenicity  
31 with tolerogenic rapamycin nanoparticles enables successful vector re-administration. *Nat*  
32 *Commun* 2018;9:4098.
- 33 146. Majowicz A, Maczuga P, Kwikkers KL, et al. Mir-142-3p target sequences reduce transgene-  
34 directed immunogenicity following intramuscular adeno-associated virus 1 vector-mediated  
35 gene delivery. *J Gene Med* 2013;15:219–232.
- 36 147. Annoni A, Brown BD, Cantore A, et al. In vivo delivery of a microRNA-regulated transgene  
37 induces antigen-specific regulatory T cells and promotes immunologic tolerance. *Blood*  
38 2009;114:5152–5161.
- 39 148. Keeler AM, ElMallah MK, Flotte TR. Gene Therapy 2017: Progress and Future Directions. *Clin*  
40 *Transl Sci* 2017;10:242–248.
- 41 149. Deverman BE, Pravdo PL, Simpson BP, et al. Cre-dependent selection yields AAV variants for  
42 widespread gene transfer to the adult brain. *Nat Biotechnol* 2016;34:204–209.
- 43 150. Chan KY, Jang MJ, Yoo BB, et al. Engineered AAVs for efficient noninvasive gene delivery to  
44 the central and peripheral nervous systems. *Nat Neurosci* 2017;20:1172–1179.
- 45 151. Huang Q, Chan KY, Tobey IG, et al. Delivering genes across the blood-brain barrier: LY6A, a  
46 novel cellular receptor for AAV-PHP.B capsids. *bioRxiv* 2019;538421.
- 47 152. Hordeaux J, Yuan Y, Clark PM, et al. The GPI-Linked Protein LY6A Drives AAV-PHP.B Transport  
48 across the Blood-Brain Barrier. *Mol Ther* 2019;27:912–921.
- 49 153. Garg T, Bhandari S, Rath G, et al. Current strategies for targeted delivery of bio-active drug  
50 molecules in the treatment of brain tumor. *J Drug Target* 2015;23:865–887.
- 51 154. Hynynen K, McDannold N, Vykhodtseva N, et al. Noninvasive MR Imaging-guided Focal  
52 Opening of the Blood-Brain Barrier in Rabbits. *Radiology* 2001;220:640–646.

- 1 155. Sheikov N, McDannold N, Vykhodtseva N, et al. Cellular mechanisms of the blood-brain  
2 barrier opening induced by ultrasound in presence of microbubbles. *Ultrasound Med Biol*  
3 2004;30:979–989.
- 4 156. Beccaria K, Canney M, Goldwirth L, et al. Opening of the blood-brain barrier with an unfocused  
5 ultrasound device in rabbits. *J Neurosurg* 2013;119:887–98.
- 6 157. Hynynen K, McDannold N, Sheikov NA, et al. Local and reversible blood–brain barrier  
7 disruption by noninvasive focused ultrasound at frequencies suitable for trans-skull  
8 sonications. *Neuroimage* 2005;24:12–20.
- 9 158. Kobus T, Vykhodtseva N, Pilatou M, et al. Safety Validation of Repeated Blood–Brain Barrier  
10 Disruption Using Focused Ultrasound. *Ultrasound Med Biol* 2016;42:481–492.
- 11 159. McMahon D, Hynynen K. Acute Inflammatory Response Following Increased Blood-Brain  
12 Barrier Permeability Induced by Focused Ultrasound is Dependent on Microbubble Dose.  
13 *Theranostics* 2017;7:3989–4000.
- 14 160. Marquet F, Tung Y-S, Teichert T, et al. Noninvasive, Transient and Selective Blood-Brain  
15 Barrier Opening in Non-Human Primates In Vivo. *PLoS One* 2011;6:e22598.
- 16 161. Stavarache MA, Petersen N, Jurgens EM, et al. Safe and stable noninvasive focal gene delivery  
17 to the mammalian brain following focused ultrasound. *J Neurosurg* 2019;130:989–998.
- 18 162. Carpentier A, Canney M, Vignot A, et al. Clinical trial of blood-brain barrier disruption by  
19 pulsed ultrasound. *Sci Transl Med* 2016;8:343re2-343re2.
- 20 163. Beccaria K, Canney M, Bouchoux G, et al. Blood-brain barrier disruption with low-intensity  
21 pulsed ultrasound for the treatment of pediatric brain tumors: A review and perspectives.  
22 *Neurosurg Focus* 2020;48:E10.
- 23 164. Pouliopoulos AN, Wu SY, Burgess MT, et al. A Clinical System for Non-invasive Blood–Brain  
24 Barrier Opening Using a Neuronavigation-Guided Single-Element Focused Ultrasound  
25 Transducer. *Ultrasound Med Biol* 2020;46:73–89.
- 26 165. Ying J, Han Z, Zeng Y, et al. Evaluation of intervertebral disc regeneration with injection of  
27 mesenchymal stem cells encapsulated in PEGDA-microcryogel delivery system using  
28 quantitative T2 mapping: a study in canines. *Am J Transl Res* 2019;11:2028–2041.
- 29 166. Fjord-Larsen L, Kusk P, Tornøe J, et al. Long-term Delivery of Nerve Growth Factor by  
30 Encapsulated Cell Biodelivery in the Göttingen Minipig Basal Forebrain. *Mol Ther*  
31 2010;18:2164–2172.
- 32 167. Emerich DF, Winn SR, Harper J, et al. Implants of polymer-encapsulated human NGF-secreting  
33 cells in the nonhuman primate: Rescue and sprouting of degenerating cholinergic basal  
34 forebrain neurons. *J Comp Neurol* 1994;349:148–164.
- 35 168. Zhang K, Hopkins JJ, Heier JS, et al. Ciliary neurotrophic factor delivered by encapsulated cell  
36 intraocular implants for treatment of geographic atrophy in age-related macular  
37 degeneration. *Proc Natl Acad Sci* 2011;108:6241–6245.
- 38 169. Birch DG, Bennett LD, Duncan JL, et al. Long-term Follow-up of Patients With Retinitis  
39 Pigmentosa Receiving Intraocular Ciliary Neurotrophic Factor Implants. *Am J Ophthalmol*  
40 2016;170:10–14.
- 41 170. Birch DG, Weleber RG, Duncan JL, et al. Randomized Trial of Ciliary Neurotrophic Factor  
42 Delivered by Encapsulated Cell Intraocular Implants for Retinitis Pigmentosa. *Am J*  
43 *Ophthalmol* 2013;156:283-292.e1.
- 44 171. Eriksdotter-Jönhagen M, Linderöth B, Lind G, et al. Encapsulated Cell Biodelivery of Nerve  
45 Growth Factor to the Basal Forebrain in Patients with Alzheimer’s Disease. *Dement Geriatr*  
46 *Cogn Disord* 2012;33:18–28.
- 47 172. Bachoud-Lévi A-C, Déglon N, Nguyen J-P, et al. Neuroprotective Gene Therapy for  
48 Huntington’s Disease Using a Polymer Encapsulated BHK Cell Line Engineered to Secrete  
49 Human CNTF. *Hum Gene Ther* 2000;11:1723–1729.
- 50 173. Bloch J, Bachoud-Lévi AC, Déglon N, et al. Neuroprotective Gene Therapy for Huntington’s  
51 Disease, Using Polymer-Encapsulated Cells Engineered to Secrete Human Ciliary Neurotrophic  
52 Factor: Results of a Phase I Study. *Hum Gene Ther* 2004;15:968–975.

- 1 174. Aebischer P, Schluep M, Déglon N, et al. Intrathecal delivery of CNTF using encapsulated  
2 genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients. *Nat Med*  
3 1996;2:696–9.
- 4 175. Lathuilière A, Schneider BL. Un implant bioactif pour prévenir la maladie d’Alzheimer.  
5 *médecine/sciences* 2017;33:81–84.
- 6 176. Lathuilière A, Mach N, Schneider BL. Encapsulated cellular implants for recombinant protein  
7 delivery and therapeutic modulation of the immune system. *Int J Mol Sci* 2015;16:10578–600.
- 8 177. Yizhar O, Fenno LE, Davidson TJ, et al. Optogenetics in Neural Systems. *Neuron* 2011;71:9–34.
- 9 178. Han X, Chow BY, Zhou H, et al. A High-Light Sensitivity Optical Neural Silencer: Development  
10 and Application to Optogenetic Control of Non-Human Primate Cortex. *Front Syst Neurosci*  
11 2011;5:18.
- 12 179. Galvan A, Stauffer WR, Acker L, et al. Nonhuman Primate Optogenetics: Recent Advances and  
13 Future Directions. *J Neurosci* 2017;37:10894–10903.
- 14 180. Han X, Qian X, Bernstein JG, et al. Millisecond-Timescale Optical Control of Neural Dynamics in  
15 the Nonhuman Primate Brain. *Neuron* 2009;62:191–198.
- 16 181. Gerits A, Vanduffel W. Optogenetics in primates: a shining future? *Trends Genet*  
17 2013;29:403–411.
- 18 182. Yazdan-Shahmorad A, Diaz-Botia C, Hanson TL, et al. A Large-Scale Interface for Optogenetic  
19 Stimulation and Recording in Nonhuman Primates. *Neuron* 2016;89:927–939.
- 20 183. Ordaz J, Wu W, Xu X-M. Optogenetics and its application in neural degeneration and  
21 regeneration. *Neural Regen Res* 2017;12:1197.
- 22 184. Siddiqi F, Wolfe JH. Stem Cell Therapy for the Central Nervous System in Lysosomal Storage  
23 Diseases. *Hum Gene Ther* 2016;27:749–757.
- 24 185. Sun JM, Kurtzberg J. Cell therapy for diverse central nervous system disorders: inherited  
25 metabolic diseases and autism. *Pediatr Res* 2018;83:364–371.
- 26 186. Ghosh HS. Adult Neurogenesis and the Promise of Adult Neural Stem Cells. *J Exp Neurosci*  
27 2019;13:117906951985687.
- 28 187. Nguyen H, Zariello S, Coats A, et al. Stem cell therapy for neurological disorders: A focus on  
29 aging. *Neurobiol Dis* 2019;126:85–104.
- 30 188. Rosenberg JB, Kaplitt MG, De BP, et al. AAVrh.10-Mediated APOE2 Central Nervous System  
31 Gene Therapy for APOE4-Associated Alzheimer’s Disease. *Hum Gene Ther Clin Dev*  
32 2018;29:24–47.
- 33 189. Ellinwood NM, Ausseil J, Desmaris N, et al. Safe, Efficient, and Reproducible Gene Therapy of  
34 the Brain in the Dog Models of Sanfilippo and Hurler Syndromes. *Mol Ther* 2011;19:251–259.
- 35 190. Sondhi D, Peterson DA, Giannaris EL, et al. AAV2-mediated CLN2 gene transfer to rodent and  
36 non-human primate brain results in long-term TPP-I expression compatible with therapy for  
37 LINCL. *Gene Ther* 2005;12:1618–1632.
- 38 191. Ciron C, Cressant A, Roux F, et al. Human  $\alpha$ -Iduronidase Gene Transfer Mediated by Adeno-  
39 Associated Virus Types 1, 2, and 5 in the Brain of Nonhuman Primates: Vector Diffusion and  
40 Biodistribution. *Hum Gene Ther* 2009;20:350–360.
- 41 192. Hadaczek P, Forsayeth J, Mirek H, et al. Transduction of Nonhuman Primate Brain with Adeno-  
42 Associated Virus Serotype 1: Vector Trafficking and Immune Response. *Hum Gene Ther*  
43 2009;20:225–237.
- 44 193. Hadaczek P, Kohutnicka M, Krauze MT, et al. Convection-enhanced delivery of adeno-  
45 associated virus type 2 (AAV2) into the striatum and transport of AAV2 within monkey brain.  
46 *Hum Gene Ther* 2006;17:291–302.
- 47 194. Salegio EA, Kells AP, Richardson RM, et al. Magnetic resonance imaging-guided delivery of  
48 adeno-associated virus type 2 to the primate brain for the treatment of lysosomal storage  
49 disorders. *Hum Gene Ther* 2010;21:1093–1103.
- 50 195. Meneghini V, Lattanzi A, Tiradani L, et al. Pervasive supply of therapeutic lysosomal enzymes  
51 in the CNS of normal and Krabbe-affected non-human primates by intracerebral lentiviral  
52 gene therapy. *EMBO Mol Med* 2016;8:489–510.

- 1 196. Naidoo J, Stanek LM, Ohno K, et al. Extensive Transduction and Enhanced Spread of a  
2 Modified AAV2 Capsid in the Non-human Primate CNS. *Mol Ther* 2018;26:2418–2430.
- 3 197. Bu J, Ashe KM, Bringas J, et al. Merits of Combination Cortical, Subcortical, and Cerebellar  
4 Injections for the Treatment of Niemann-Pick Disease Type A. *Mol Ther* 2012;20:1893.
- 5 198. Jarraya B, Boulet S, Scott Ralph G, et al. Dopamine Gene Therapy for Parkinson’s Disease in a  
6 Nonhuman Primate Without Associated Dyskinesia. *Sci Transl Med* 2009;1:2ra4-2ra4.
- 7 199. Bucher T, Colle M-A, Wakeling E, et al. scAAV9 Intracisternal Delivery Results in Efficient Gene  
8 Transfer to the Central Nervous System of a Feline Model of Motor Neuron Disease. *Hum*  
9 *Gene Ther* 2013;24:670–682.
- 10 200. Naidoo J, Stanek LM, Ohno K, et al. Extensive Transduction and Enhanced Spread of a  
11 Modified AAV2 Capsid in the Non-human Primate CNS. *Mol Ther* 2018;26:2418–2430.
- 12 201. Ohno K, Samaranch L, Hadaczek P, et al. Kinetics and MR-Based Monitoring of AAV9 Vector  
13 Delivery into Cerebrospinal Fluid of Nonhuman Primates. *Mol Ther - Methods Clin Dev*  
14 2019;13:47–54.
- 15 202. Gray SJ, Nagabhushan Kalburgi S, McCown TJ, et al. Global CNS gene delivery and evasion of  
16 anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates.  
17 *Gene Ther* 2013;20:450–9.
- 18 203. Taghian T, Marosfoi MG, Puri AS, et al. A Safe and Reliable Technique for CNS Delivery of AAV  
19 Vectors in the Cisterna Magna. *Mol Ther* 2020;28:411–421.
- 20 204. Wang H, Yang B, Qiu L, et al. Widespread spinal cord transduction by intrathecal injection of  
21 rAAV delivers efficacious RNAi therapy for amyotrophic lateral sclerosis. *Hum Mol Genet*  
22 2014;23:668–681.
- 23 205. Choudhury SR, Fitzpatrick Z, Harris AF, et al. In Vivo Selection Yields AAV-B1 Capsid for Central  
24 Nervous System and Muscle Gene Therapy. *Mol Ther* 2016;24:1247–1257.
- 25 206. LeWitt PA, Rezai AR, Leehey MA, et al. AAV2-GAD gene therapy for advanced Parkinson’s  
26 disease: a double-blind, sham-surgery controlled, randomised trial. *Lancet Neurol*  
27 2011;10:309–319.
- 28 207. Christine CW, Starr PA, Larson PS, et al. Safety and tolerability of putaminal AADC gene  
29 therapy for Parkinson disease. *Neurology* 2009;73:1662–1669.
- 30 208. Marks WJ, Bartus RT, Siffert J, et al. Gene delivery of AAV2-neurturin for Parkinson’s disease:  
31 a double-blind, randomised, controlled trial. *Lancet Neurol* 2010;9:1164–1172.
- 32 209. Souweidane MM, Fraser JF, Arkin LM, et al. Gene therapy for late infantile neuronal ceroid  
33 lipofuscinosis: neurosurgical considerations. *J Neurosurg Pediatr* 2010;6:115–122.
- 34 210. Tardieu M, Zérah M, Gougeon ML, et al. Intracerebral gene therapy in children with  
35 mucopolysaccharidosis type IIIB syndrome: an uncontrolled phase 1/2 clinical trial. *Lancet*  
36 *Neurol*. Epub ahead of print 2017. DOI: 10.1016/S1474-4422(17)30169-2.
- 37 211. Eberling JL, Jagust WJ, Christine CW, et al. Results from a phase I safety trial of hAADC gene  
38 therapy for Parkinson disease. *Neurology* 2008;70:1980–1983.
- 39 212. Muramatsu S, Fujimoto K, Kato S, et al. A Phase I Study of Aromatic L-Amino Acid  
40 Decarboxylase Gene Therapy for Parkinson’s Disease. *Mol Ther* 2010;18:1731–1735.
- 41 213. Lewis O, Woolley M, Johnson D, et al. Chronic, intermittent convection-enhanced delivery  
42 devices. *J Neurosci Methods* 2016;259:47–56.
- 43 214. Miranpuri G, Hinchman A, Wang A, et al. Convection Enhanced Delivery: A Comparison of  
44 infusion characteristics in ex vivo and in vivo non-human primate brain tissue. *Ann Neurosci*  
45 2013;20:108–14.
- 46 215. Brady ML, Raghavan R, Singh D, et al. In vivo performance of a microfabricated catheter for  
47 intraparenchymal delivery. *J Neurosci Methods* 2014;229:76–83.
- 48 216. Gill T, Barua NU, Woolley M, et al. In vitro and in vivo testing of a novel recessed-step catheter  
49 for reflux-free convection-enhanced drug delivery to the brain. *J Neurosci Methods*  
50 2013;219:1–9.
- 51 217. Lewis O, Woolley M, Johnson DE, et al. Maximising coverage of brain structures using  
52 controlled reflux, convection-enhanced delivery and the recessed step catheter. *J Neurosci*

1 Methods 2018;308:337–345.  
2 218. Wernicke AG, Lazow SP, Taube S, et al. Surgical Technique and Clinically Relevant Resection  
3 Cavity Dynamics Following Implantation of Cesium-131 Brachytherapy in Patients With Brain  
4 Metastases. *Oper Neurosurg* 2016;12:49–60.  
5 219. Singleton W, Collins A, Bienemann A, et al. Convection enhanced delivery of panobinostat  
6 (LBH589)-loaded pluronic nano-micelles prolongs survival in the F98 rat glioma model. *Int J*  
7 *Nanomedicine* 2017;Volume 12:1385–1399.  
8  
9  
10

1 **Legends**

2 **Figure 1:**

3 (A) Circulation of the CSF. Secretion by the choroid plexus and circulation within the ventricles  
4 to the foramen of Magendie and Lushka (black arrows) to the extraventricular subarachnoid  
5 spaces. Then circulation around the brain and the spinal cord (blue arrows), to the resorption  
6 spaces (mainly the superior sagittal sinus)

7 (B) Intrathecal injection targeting the spinal cord

8 (C) Injection within the cisterna magna targeting the more superficial area of the brain (mainly  
9 the cortical zone)

10 (D) Intraventricular injection targeting the deepest regions of the brain (mainly the basal  
11 ganglia and the subventricular nucleus. Notice that the hippocampus region can be  
12 theoretically reached by cisternal or intraventricular injection

13 (E) Following the CSF flow, a part of the vectors will reach the resorption areas and join the  
14 cerebral blood stream and then the cerebral circulation to the peripheral organs

15

16

17 **Figure 2: Intracerebral injection in NHP and humans**

18 (A) Personal data of intracerebral gene therapy with 12 intracerebral delivery in white matter  
19 for San Filippo A and MLD. (B) Neuronavigation software for preplanning. (C) Delivery  
20 improvement with MRI Smartflow catheters; (D) Immediate Post-operative MRI and (E) Brain  
21 delivery in NHP with the same MRI smartflow catheters.


22

23

24


1 **Figure 1:**

2



3

1 **Figure 2: Intracerebral injection in NHP and humans**



2

**Table 1: Intraparenchymal delivery in large animal models**

Transgene / Pathology	Target	Specie	Age	Number	Vector / Buffer	Dose	Volume	Speed	Results	Article
ARSA for MLD	3 areas of the centrum semiovale white matter or in the deep gray nuclei (caudate nucleus, putamen, thalamus)	NHP	2–3-year-old	6	AAV 2 - 5	1.9.10 <sup>12</sup> vg to 3.8.10 <sup>11</sup> vg	40 µl/deposit	3 µl/min	AAV vector was detected in a brain volume of 12–15 cm <sup>3</sup> that corresponded to 37–46% of the injected hemisphere. ARSA enzyme was expressed in multiple interconnected brain areas over a distance of 22–33 mm. ARSA activity was increased by 12–38% in a brain volume that corresponded to 50–65% of injected hemisphere	37
GDNF for PD	striatum, substantia nigra, caudate nucleus	NHP, rhesus	8 aged (25years) + 5 young adults	8+5	Lentiviral vector				Extensive GDNF expression with anterograde and retrograde transport was seen in all animals. In aged monkeys, lenti-GDNF augmented dopaminergic function. In MPTP-treated monkeys, lenti-GDNF reversed functional deficits and completely prevented nigrostriatal degeneration. Additionally, lenti-GDNF injections to intact rhesus monkeys revealed long-term gene expression (8 months). In MPTP-treated monkeys, lenti-GDNF treatment reversed motor deficits in a hand-reach task	78
APOE2-HA for AD	intrahippocampal	NHP	4- to 7-year-old	2	Recombinant AAVrh.10	5.10 <sup>12</sup> vg (vg; 0.7–1.2. 10 <sup>12</sup> vg/kg	15 µL per injection site	1 µL/min	AAVrh.10hAPOE2-HA directly into the hippocampus/entorhinal cortex achieved easily detectable, diffuse ApoE2 expression in targeted regions using this route of delivery compared to the non-treated controls	188
NAGLU for lysosomal disease	white matter	dog		25	AAV2.5 AAV 5.5	5.10 <sup>11</sup> vg, 1.5.10 <sup>12</sup> vg/ml; 8.10 <sup>11</sup> vg, 2.5.10 <sup>12</sup> vg/ml; 20.10 <sup>11</sup> vg, 6.5.10 <sup>12</sup> vg/ml	8 x 40µl	2 µL/min)	In immunosuppressed dogs, vector was efficiently delivered throughout the brain, induced α-N-acetylglucosaminidase production, cleared stored compounds and storage lesions	189
CLN2 for Late infantile neuronal ceroid lipofuscinosis	head and body of the caudate nucleus, hippocampus and overlying cerebral cortex	NHP			AAV 2	3.6 × 10 <sup>11</sup> pu	180 µl	1 µl/min	Assessment at 5 and 13 weeks demonstrated widespread detection of TPP-I in neurons, but not glial cells, at all regions of injection. The distribution of TPP-I-positive cells was similar between the two time points at all injection sites	190
α-iduronidase	putamen and centrum semiovale	NHP		6	(rAAV2/1, rAAV2/2, and rAAV2/5	1.4.10 <sup>10</sup> vg	2x50 µl		global diffusion throughout the brain was not significantly different between the three serotypes. However, rAAV2/1 and rAAV2/5 resulted in higher vector copy numbers per cell than did rAAV2/2, respectively, in the brain and the distal neuronal structures	191
CMV-hrGFP	corona radiata, striatum, and basal forebrain	NHP cynomolgus		8	AAV1	2.3 to 6.9 10 <sup>11</sup> vg	10 to 150 µl	0.2 to 3 µl/min	AAV1 is actively trafficked to regions distal from the infusion site. In addition to neuronal transduction, a significant nonneuronal cell population was transduced by AAV1 vector	192
AAV-TK ,AAV2-AADC		NHP			AAV2				at least 75% of the putamen could be covered by a single infusion of the vector	193
human acidic sphingomyelinase For Nieman Pick disease	brainstem (1 site) and thalamus (bilateral)	NHP		4	AAV2	1.10 <sup>12</sup> vg/ml	33 to 199 µl	0,1 increased at 10-min intervals to 0.2, 0.5, 0.8, 1.0, and 2.0 µl/min	We found that enzymatic augmentation in brainstem, thalamic, cortical, as well subcortical areas provided convincing evidence that much of the large NHP brain can be transduced with as few as three injection sites.	194
hARSA	external capsule and thalamus	NHP	2-3 months	9	Lentivirus	5.10 <sup>7</sup> TU/injection site	80 µl	NA	favorable safety profile and consistent pattern of LV transduction and enzyme biodistribution. Efficient gene transfer in neurons, astrocytes, and oligodendrocytes close to the injection sites resulted in robust production and extensive spreading of transgenic enzymes in the whole CNS	195
<u>heparan sulfate</u>	thalamus + ICV	NHP			AAV2				The combination of thalamic and intracerebroventricular delivery resulted in transduction of oligodendrocytes in superficial cortical layers and neurons in deeper cortical layers	196

<u>proteoglycan receptor</u>										
hARSA	White matter, 6 sites	NHP		14	AAVrh10	5.5.10 <sup>11</sup> vg/hemisphere	30 ll for each deposit, 0.5 ll/min	0.5 ll/min	After injection of the 1 - dose, AAVrh.10- hARSA vector was detected in a large part of the injected hemisphere, while ARSA activity exceeded the normal endogenous activity level by 14–31%	11
hASM for NP-A	12 sites : motor cortex, occipital cortex, striatum and thalamus, hippocampus, cerebellum	NHP	2Y/o	2	AAV1	2.6. 10 <sup>12</sup> gc	520 µl total	NA	a combination cortical, subcortical, and cerebellar injection protocol could provide therapeutic levels of hASM to regions of the NHP brain	197
ARSA	6 sites deep gray matter + white matter	NHP	3- to 6-year-old	11	AAVrh.10	1.5.10 <sup>12</sup> vg	50-µl/deposit	1-3 microl/min	Of the five routes studied, administration to the white matter generated the broadest distribution of ARSA, with 80% of the brain displaying more than a therapeutic (10%) increase in ARSA activity above PBS controls	85
SGSH	Subcortical white matter	Dogs		3	AAVrh.10	1. 10 <sup>12</sup> vg and 2. 10 <sup>12</sup> vg	500µl/deposit (2 or 4 deposits)	10ul/min	extensive distribution into both rostral and caudal brain regions. significant amounts of vector DNA were found in only 37% of brain punches, increases of SGSH activity of 20% or greater relative to vehicle-treated animals were found in 78% of the brain punches tested 4 weeks after injection.	77
SGSH	Subcortical white matter	NHP	4 years	2	AAVrh.10	7.2. 10 <sup>11</sup> vg	50µl/deposit (4 deposits)	5ul/min	presence of vector DNA in a limited proportion (11%) of brain punches, but a wide distribution of SGSH enzymatic activity of 20% or more of control levels in the near totality (97%) of the NHP brain 6 weeks after injection.	77
	striatum	NHP			tricystronic lentiviral vector				restoration of extracellular concentrations of dopamine and corrected the motor deficits for 12 months without associated dyskinesias	198

**Table 2: Intracerebroventricular administration in large animal models**

Transgene / Pathology	Target	Specie	Age	Number	Vector / Buffer	Dose	Volume	Speed	Results	Article
shRNA SMN +GFP or SMN	Cisterna Magna	Pig	5 days	14	scAAV9	6.5.10 <sup>12</sup> vg/kg (shSMN)		slow and constant	reduction of SMN mRNA levels by 73% in motoneurons postnatally	81
GFP	Cisterna Magna	NHP	adult	3	AAV9	1.1.10 <sup>13</sup> vg	2ml		Presence of serious adverse side effects with a non- pronounced cellular loss in the Purkinje layer. No side effect in animal with more restricted GFP expression.	84
hAADC	Cisterna Magna	NHP	adult	1	AAV9	3.10 <sup>13</sup> vg	2ml		broad transduction throughout cerebellum and brain cortex similar to what was obtained with GFP but no cerebellar cell dysfunction	
GFP	Cisterna Magna	Sheep	adult	3	LV	1.3.10 <sup>8</sup> TU (N=2) and 1.10 <sup>9</sup> TU	10 and 100ul	1min	GFP expression in cells along the needle track and in the brain parenchyma up to 2.5 mm rostral-caudal and lateral to the injection site. Both neurons and astrocytes were similarly transduced	80
VEGF	Cisterna Magna	cat	adult	3	ssAAV1	10 <sup>12</sup> /kg	1ml/kg		strong expression of the transgene in the spinal cord, even at the lowest dose.	199
VEGF	Cisterna Magna	cat	adult	4	scAAV9	10 <sup>12</sup> /kg and 10 <sup>13</sup> /kg	1ml/kg		numerous GFP-positive neurons in the cortex, thalamus and cerebellum	
CAG-GFP	Cisterna Magna	NHP	adult	2	AAV7 (saline, 5% sorbitol, 0.001% pluronic F-68)	2.10 <sup>13</sup> vg	2ml	0.5ul/min	cells throughout the NHP brain from prefrontal to occipital cortex and cerebellum, sparsely in striatum. GFP-positive cells clustered around blood vessels weak transduction in periphery. GFP-positive cells at all spinal cord levels, in motor neurons and some astrocytes DRG of the cervical region, proximal to the site of injection and some satellite glial cells surrounding DRG neurons	70
CAG-GFP	Cisterna Magna	NHP	adult	2	AAV9 (saline, 5% sorbitol, 0.001% pluronic F-68)	1.8.10 <sup>13</sup> vg	2ml	0.5ul/min	cells throughout the brain from prefrontal to occipital cortex and cerebellum, sparsely in striatum. GFP-positive cells clustered around blood vessels. GFP-positive cells at all spinal cord levels, in motor neurons and some astrocytes. DRG of the cervical region, proximal to the site of injection and some satellite glial cells surrounding DRG neurons	
GFP	Cisterna Magna	NHP	2-3 years	3	sc AAV9	1.25.10 <sup>13</sup> vg	3+3ml		15–50% motor neuron transduction throughout the cervical, thoracic, and lumbar segments. GFP-positive pyramidal neurons; Purkinje cells throughout the cerebellar cortex were also efficiently transduced. not detected in the liver and spleen of the monkeys	87
GFP	Cisterna Magna	Dog	adult	7	AAV9	2.10 <sup>13</sup> vg	1ml	100ul/min or bolus in 15s	widespread CNS transduction	
human SGSH	Cisterna Magna	Dog	adult	2	AAV9	2.10 <sup>13</sup> vg	1ml	bolus in 15s	the loss of transgene expression was due to the use of a nonspecies-specific transgene	89
canine SGSH	Cisterna Magna	Dog	adult	3	AAV9	2.10 <sup>13</sup> vg	1ml	bolus in 15s	activity peaked 2–4 weeks, but persistent at high levels for 3 months	
eGFP	Cisterna Magna	NHP	adult	4	ssAAV9	5.10 <sup>12</sup> /kg and 2.5.10 <sup>12</sup> /kg			substantial vector deposition in the brain and spinal cord (1VGC) Vector copy numbers quite high in liver and spleen.	88
ApoE2/HA	Cisterna Magna	NHP	adult	3	AAVrh10	5.10 <sup>13</sup> vg	1-1.3ml	0.5ml/min	CM: 92.0% of cubes had vector levels >1,000 copies/ig DNA, heavy staining of the ependymal cells of the choroid plexus, but also in areas around the frontal and mid-brain, including the hippocampal region, as well as areas around the posterior of the brain and spinal cord.	86
CAG-GFP	Cisterna Magna	NHP	adult	2	AAV9 sc	1.8.10 <sup>13</sup> vg	2ml	0.5ul/min	prefrontal to occipital cortex and mainly cerebellum. number and intensity of GFP-positive cells were much greater after CM infusion than ICA delivery. greater astrocytic than neuronal tropism via both routes. not shield against AAV antibodies. Sparse GFP expression was observed in the spleen and liver.	83
CMV-hAADC	Cisterna Magna	NHP	adult	5	AAV9	0.3 / 1 / 3.10 <sup>13</sup> vg	2ml	0.5ul/min	prefrontal to occipital cortex and mainly cerebellum. number and intensity of GFP-positive cells were much greater after CM infusion than ICA delivery, greater astrocytic than neuronal tropism via both routes. not shield against AAV antibodies. Sparse GFP expression was observed in the spleen and liver	
GUSB	Cisterna Magna	Dogs	adult and 2months	7	AAV9	1.8.10 <sup>13</sup> vg	1ml	1-2 min	ICV and IC vector administration resulted in similarly efficient transduction throughout the brain and spinal cord. ICV cohort developed encephalitis associated with a T-cell response to the transgene product, a phenomenon that was not observed in the IC cohort	99
GFP	Cisterna Magna	NHP	adult	2	AAV9	1.83.10 <sup>12</sup> vg	1.5ml		substantial transduction was found in the hypothalamus along the third ventricle and in the central gray surrounding the Sylvian aqueduct. extensive transduction was found in the subcommissural organ, located within the dorsal third ventricle, whereas some (GFP)-positive vestibular neurons were found near the fourth ventricle.	90

GFP	Cisterna Magna	NHP	adult	2	AAV2,5	2.10 <sup>12</sup> vg	1.5ml		very strong transduction of the ependymal structure	
GFP	Cisterna Magna	Cat	50 days	6	scAAV9	10 <sup>12</sup> vg/kg	1-1,5ml		more efficiently targeting of MNs of the lumbar (99%) than of the cervical regions (84%) spinal cord. numerous oligodendrocytes were also transduced in the brain and in the spinal cord white matter of young cats, but not of neonates	92
CAG-ARSA-FLAG / MLD	lateral ventricle	NHP	adult	2	AAVrh10 in PBS	1,5.10 <sup>12</sup> vg	75ul	15ul/min	almost no copies and no ARSA expression (11/83=13%) whereas gold standard: white matter 82%	85
ApoE2/HA	left or right ventricle	NHP	adult	3	AAVrh10	5.10 <sup>13</sup> vg	1-1.3ml	0.2ml/min	ICV: 90.0% of cubes had vector levels >1,000 copies/lg DNA, heavy staining of the ependymal cells of the choroid plexus, but also in areas around the frontal and mid-brain, including the hippocampal region, as well as areas around the posterior of the brain and spinal cord.	86
CAG-TPP1 /CLN2	lateral ventricles +/- CM	Dog (TPP deficient)	10-11 days	7	AAV2	1.1.10 <sup>12</sup> vg	1,5ml		TPP1 activity in CSF detectable at 5 days but no more detectable at 2 months	82
IDUA / MPS I	suboccipital	Cat	adult	5	AAV9	10 <sup>12</sup> vg/kg	1-2ml	bolus	complete correction of biochemical and histological manifestations throughout the CNS. antibody responses against IDUA which reduced detectable enzyme without substantially reducing efficacy. no evidence of toxicity	88
GFP	ICV	Dog	adult	2	AAV9	2.10 <sup>13</sup> vg	1ml	bolus in 15s	Comparable with CM administration	89
GFP	ICV	NHP			AAV2 - HBKO	1.8.10 <sup>13</sup> vg	1.5ml	1-10ul/min	widespread cortical transduction, with oligodendrocytes transduced. Robust motor neuron transduction observed in all levels of the spinal cord	200
hASM-HA	CM	NHP	adult	6	AAV9	1.32.10 <sup>13</sup> vg	6ml	1ml/min (n=3) or 1ml/h (n=3)	Infusion of the vector in brain and spinal cord after MRI but only with High speed delivery	201
hASM-HA	ICV	NHP	adult	2	AAV9	1.32.10 <sup>13</sup> vg	6ml	1ml/min (n=3) or 1ml/h (n=3)	much larger cortical distribution at the end of the acquisitions, including occipital cortical regions that were not covered by any other routes of delivery	201
ciDUA	Suboccipital	Dogs	28 days	3	AAV9	10 <sup>12</sup> vg/kg	0.5ml	bolus	vector distributed throughout the CNS. supraphysiologic expression of IDUA in CSF, which declined to the normal range	94

**Table 3 : Intrathecal administration in large animal models**

Transgene / Pathology	Target	Specie	Age	Number	Vector / Buffer	Dose	Volume	Speed	Results	Article
GUSB / MPS VII	IT	Dog	18-20 days	3	AAV9	5.10 <sup>12</sup> vg/kg	1-2ml	1-2min	~50-fold higher expression and a more profound effect on markers of disease than IV delivery	93
GUSB / MPS VII	IT	Dog	18-20 days	2	AAV10	5.10 <sup>12</sup> vg/kg	1-2ml	1-2min	~50-fold higher expression and a more profound effect on markers of disease than IV delivery	
GUSB	Lumbar L4/L5	NHP	adult	6	AAV9	2.10 <sup>13</sup> vg	5ml		transduction efficiency was not improved by placing animals in the Trendelenburg position after injection.	99
GFP	Lumbar cistern	NHP	adult	8	AAV9	1.83.10 <sup>12</sup> vg (N=6) and 5.5.10 <sup>12</sup> vg (N=2)	1ml		very strong transduction of the ependymal structure	202
GFP	L4/L5	NHP	adult	7	scAAV9	1.10 <sup>13</sup> vg/kg	1ml	Bolus	73% of motor neurons targeted in the lumbar region, 53% of motor neurons targeted in thoracic region, and 29% in the cervical spinal cord; tilting for 10 minutes was sufficient to increase motor neuron transduction to 55, 62, and 80% in the cervical, thoracic, and lumbar region. GFP in all brain regions with particularly strong signals in the hippocampus and in the motor cortex. In the brainstem, high transduction of the hypoglossal and trigeminal nuclei, with more than 60 and 75% motor neurons. In the cerebellum, both Purkinje cells and cells of the nuclear layer demonstrated high GFP expression	13
miRNA anti SOD1	L5 and catheter	NHP	adult	32	AAV10		2.5ml	7.5ml/hour	preimplantation of a catheter and placement of the subject with head down at 30° during intrathecal infusion. efficient delivery and effective silencing of the SOD1 gene in motor neurons	98
GFP	L5/L6	Pig	5 days	1	AAV9	5.2.10 <sup>12</sup> vg/kg	0.25ml	bolus	Extensive motor neuron transduction at all levels of the spinal cord. The brain regions with the highest levels of GFP expression were cerebellar Purkinje cells, nerve fibers within the medulla as well as discrete nuclei, such as the olivary nucleus. Expression within the rest of the brain was restricted to scattered cells near the meningeal surfaces. No obvious expression in periphery	96
miRNA anti SOD1	Lumbar	Marmosets	less than 4 years	9	AAV10	6.10 <sup>12</sup> vg/kg	300ul	bolus	high transduction of lumbar spinal cord, than thoracic and cervical . High liver transduction. In brain, mild to good transduction, depending on the regions. Robust GFP staining was seen at the injection site at LSC level all the way to CSC level.	95
GFP	L5 with catheters	Pigs	2 months	2	scAAV9	3 x 1.10 <sup>12</sup> vg	3x0.5ml	Bolus	GFP expression in 10–30% of the motor neurons, and one segment (L2) showed GFP expression in 35% of the motor neurons.	87
eGFP	Lumbar punctura	NHP	adult	2	ssAAV9	2.5.10 <sup>12</sup> /kg			10x lower gene transfer throughout the spinal cord, and up to 100-fold less in the brain compare to CM. Vector copy numbers quite high in liver and spleen.	88
hASM-HA	Lumbar	NHP	adult	3	scAAV9	1.32.10 <sup>13</sup> vg	6ml	1ml/min or 1ml/hour	Leakage of the infusion in musculature	201
GFP	Lumbar	Sheep	adult	2	scAAV9		15ml	1ml/min	the frontal, occipital, and parietal cortices exhibited extensive neuronal and glial cell transduction, whereas in the motor cortex glial transduction was primarily observed. Scarce positive neurons were present in the caudate, putamen, and thalamus. Strong GFP staining was noted in the cerebellum, including Purkinje cells, deep cerebellar nuclei and adjacent	203

									axons in the white matter, cerebellar peduncles, and brainstem. Robust neuronal transduction was observed along the entire length of the spinal cord, from cervical to lumbar	
miRNA anto SOD1	Lumbar L4/L5	Marmoset	adult	1	AAV10	2.7.10 <sup>12</sup> vg	250ul	slow bolus	robust expression in motor neurons along the full length of the spinal cord	204

**Table 4 : Intravenous administration in large animal models**

Transgene / Pathology	Target	Specie	Age	Number	Vector / Buffer	Dose	Volume	Speed	Results	Article
CAG-GFP	Internal carotid artery	NHP		3	AAV9 sc	3.10 <sup>13</sup> vg	11 / 21 / 40ml	4ml/min	broader transgene distribution throughout the CNS, extending through several cortical regions. Scattered GFP-expressing cells were found from the pre- frontal to occipital cortex, and in the cerebellum. widespread peripheral organ transduction (Liver and Spleen)	83
CAG-ARSA-FLAG / MLD	Intra-arterial (right middle cerebral artery)	NHP	adult	1	AAVrh10 in PBS	1,5.10 <sup>12</sup> vg	12ml	bolus	almost no copies and no ARSA expression (6/77=7,8%) whereas gold standard: white matter 82%	85
GUSB / MPS VII	IV	Dog	3 days	1	AAV9	2.10 <sup>13</sup> vg/kg	1-2ml	1-2min	limited GUSB expression in cortical and hippocampal neurons, and Purkinje cells, while average expression levels in other brain tissues were only ~1 to 6% of normal levels Similar to AAV10 injected animals. Clear motoneurons transduction	93
GUSB / MPS VII	IV	Dog	3 days	1	AAV10	2.10 <sup>13</sup> vg/kg	1-2ml	1-2min	limited GUSB expression in cortical and hippocampal neurons, and Purkinje cells, while average expression levels in other brain tissues were only ~1 to 6% of normal levels Similar to AAV9 injected animals. Clear motoneurons transduction	
NAGLU	IV	NHP	adult	8	ssAAV9	1 (N=2) or 2.10 <sup>13</sup> vg/kg (N=4)	5ml	bolus	global CNS and broad somatic transduction. evident vector transduction throughout the brain. Low levels of preexisting anti-AAV9 antibodies did not diminish vector transduction but high-level of preexisting anti-AAV9 Abs lead to reduced transduction in liver and other somatic tissues, but had no detectable impact on transgene expression in the brain.	40
GFP	carotid artery	Cat	2 months	1	AAV-B1	3.4.10 <sup>12</sup> vg		Bolus	sparse but widespread neuronal gene transfer throughout the brain. AAV-B1 transduced neurons in the cerebral cortex, striatum, hippocampus, thalamus and Purkinje neurons in the cerebellum and motor neurons throughout the midbrain. no indication that AAV-B1 transduced endothelial cells. negligible transduction of liver was observed with AAV-B1, while strong gene transfer to skeletal and cardiac muscle could be detected	205
VEGF	jugular vein	Cat	2 days	3	scAAV9	10 <sup>12</sup> vg/kg	1ml/kg	bolus	no detectable protein	92
GFP	jugular vein	Cat LIX1	7 days	2	scAAV9	1.5.10 <sup>12</sup> vg	1ml	Bolus	GFP was detected from the cervical part of the spinal cord to the cauda equina in a number of cells in the ventral spinal cord. In neonates, up to 39 and 34% of the MNs. Nerve fibers of the fasciculi gracilis and cuneatus dorsal sensory tracts also contained large amounts of GFP.	91
GFP	jugular vein	Cat LIX1	7 weeks	2	scAAV9	1.2.10 <sup>12</sup> vg	3.6ml	Bolus	up to 15% of MNs transduction observed	
cIDUA	jugular vein	Dogs	90 days	4	AAV8	3.10 <sup>12</sup> vg/kg	0.5-1ml	bolus	mild in serum IDUA activity	94
GFP	saphenous or intracarotid	NHP	adult	4	sc AAV9	0.9- 1.10 <sup>13</sup> vg/kg	10ml/kg	2.5ml/min	predominant transduction of glia in NHPs after both intravenous and intra-arterial administration	90

VEGF	jugular vein	cat	adult	6	scAAV9	10 <sup>12</sup> /kg (N=2) and 10 <sup>13</sup> /kg (N=4)	1-2ml		transduction of the spinal cord occurs in neonatal and adult cats but the level of transgene expression remained low in both adult and neonate-injected animals. transduction was detected essentially in liver.	199
GFP	saphenous vein	NHP	adult	1	AAV9	1-3.10 <sup>14</sup> vg/kg		bolus	only MN and cells with glial morphology that were sparsely scattered. most abundant number of GFP-expressing cells in all cortical regions lateral geniculate midbrain, pons and medulla. Subcortical structures such as thalamus and putamen were also GFP+ but at a lower cell density. mostly glial transduction with microglia and astrocytes. high levels of vector in liver and also other peripheral tissues	96
GFP	catheter through the brachial artery until aorta	NHP	adult	1	AAV9	2.7.10 <sup>13</sup> vg/kg		bolus	Motor neuron targeting extensive transgene expression throughout the entire brain. most abundant number of GFP-expressing cells in all cortical regions lateral geniculate, midbrain, pons and medulla. Subcortical structures such as thalamus and putamen were also GFP+ but at a lower cell density. glial transduction with microglia and astrocytes. Liver, heart, testis and largely peripheral transduction	
IDUA	IV	NHP	adult	2	AAV9	2.5.10 <sup>13</sup> vg/kg 7.5.10 <sup>13</sup> vg/kg	1ml	Bolus	vector well tolerated. GFP expression was detected in most non-CNS tissues, including liver and muscle, kidney, pancreas, heart, spleen, and pituitary. very low transduction was observed the frontal cortex and spinal cord and hippocampus and cerebellum but transduction in DRG. Good tolerance of the virus	45
IDUA	IV	NHP	adult	2	AAVPHP.B	2.5.10 <sup>13</sup> vg/kg 7.5.10 <sup>13</sup> vg/kg	1ml	Bolus	vector well tolerated. GFP expression was detected in most non-CNS tissues, including liver and muscle, kidney, pancreas, heart, spleen, and pituitary equivalent to AAV9 except for in skeletal muscle, where transduction was higher for PHP.B vector well tolerated. Immune response against the virus	45
eGFP	IV	NHP		1	ssAAV9	2.10 <sup>13</sup> vg/kg			vector distribution to the CNS was substantially lower than that achieved at four- to eightfold lower doses via CM	88

**Table 5 : Clinical trials with Intra CSF or intravenous administration**

Transgene / Pathology	Target	Age	Number	Vector / Buffer	Dose	Volume	Speed	Identification of the trial and results if available	Article
CLN6 / Batten	IT		13	AAV9	1.5.10 <sup>13</sup> vg			NCT02725580, Phase I/II	NA
JeT-GAN / Giant Axonal Neuropathy	IT			AAV9				NCT02362438	206
NAGLU / MPSIIB				scAAV9					NA
SGSH / MPSIIIA	IV		9 ?	AAV sc9	5.10 <sup>12</sup> vg/kg (n=3) and 1.10 <sup>13</sup> vg/kg (n=1)			NCT02716246, Phase I/II	NA
SMN type 1 / SMA	IV	child	15 (cohort 1 n=3, cohort 2 n=12)	AAV9	6.7.10 <sup>13</sup> vg/kg cohort 1 and 2.10 <sup>14</sup> vg/kg cohort 2			NCT02122952, Phase I/II , longer survival, motor improvement	41
SMN	IV	child	6	AAV9				NCT03837184, Phase III	NA
SGSH / MPSIIIA	IV		12	scAAV9	3.10 <sup>13</sup> vg/kg			NCT04088734	NA
GLB1 / GM1 type I and II	IV	6 months – 1 year for GM1 type I and 2-12 for GM1 type II	45	AAV9	1.5 to 4.5.10 <sup>13</sup> vg/kg			NCT03952637	NA
hTERT/ AD	IV /IT	45 years and older	5					NCT04133454	NA
HEXA / HEXB Tay sachs	IT	7 and 30 months old	2	AAVrh8	HEXA vector (0.5 mL, 9.9. 10 <sup>12</sup> vg/mL) mixed with HEXB (0.413 mL, 1.2 .10 <sup>13</sup>	12ml	1ml/min		203

					vg/mL) to generate a 1:1 equimolar formulation				
GBA / Parkinson	ICM	40 to 75 years	16		Low and high dose			NCT04127578	NA
GRN / Fronto temporal dementia	ICM	30 to 80 years	15		Low, medium and high dose			NCT04408625	NA
IDUA / MPS1	ICM	4 months and older	5	AAV9	1 and 5.10 <sup>10</sup> gc/kg			NCT03580083	NA
IDS / MPS2	ICM	4 months to 5 years	6	AAV9	1.3 and 6.5.10 <sup>10</sup> gc/kg			NCT03566043	NA
CLN3	IT	children	7	scAAV9	Low or high dose			NCT03770572, Phase I/IIa	NA

**Table 6 : Clinical trials with Intra parenchymal administration**

Transgene / Pathology	Target	Age	Number	Vector / Buffer	Dose	Volume	Speed	Identification of the trial and results if available	Article
AADC/ParkD	Striatum	adult		AAV2				NCT00229736, Increased risk of intracranial hemorrhage, Phase I motor improvement	<sup>207</sup>
TPP-1/LINCL	12 sites in WM	Children		AAV2				Unsuccessful but suggestion of slowing progression of disease	<sup>207</sup>
NTN (CERE-120) /Parkinson	Putamen		12	AAV2	1.4.10 <sup>11</sup> vg/mL and 5.7.10 <sup>11</sup> vg/mL	40 µl		well tolerated, significant motor score improvement 6 months after infusion	<sup>208</sup>
NTN (CERE-120) /Parkinson	Putamen	Adult 35-75 years	38 /20 sham	AAV2	5.7.10 <sup>11</sup> vg/mL	40 µl/ hemisphere		NCT00252850, CERE 120, double blinded clinical trial, afetr 1 year : 13/38, 4/20 sham reacted adversely to the injection, no clinically significant improvement versus placebo at 12 months	<sup>208</sup>
NTN (CERE-120) / Parkinson	Putamen + Subst Nigra, bilateral	Adult 35-70 years	60	AAV2	2.4.10 <sup>12</sup> vg			NCT00985517, Phase I, double blinded, safely tolerated, 5 years f-up, no significant improvement	<sup>208</sup>
AADC / Parkinson	Putamen		10	AAV2	9.10 <sup>10</sup> vg and 3.10 <sup>11</sup> vg			Low and high vector dose, well tolerated, dose dependent improvement in dopamine synthesis Elevated PET signal persisted over 4 years in both groups	<sup>208</sup>
Prosavin	Striatum	Adult 48-65 years	15	Lentiviral EIAV	1.9.10 <sup>7</sup> ; 4.10 <sup>7</sup> and 1.10 <sup>8</sup> TU			NCT01856439, Phase I /II, safely tolerated, modest effects but patients with higher dose of ProSavin required lower dose of dopamine (enhanced dopamine production ?)	<sup>208</sup>
NGF (CERE-110) / Alzheimer		Adult 55-80 years	49	AAV2	2.10 <sup>11</sup> vg			NCT00876863, Phase II, inefficient, safely tolerated	<sup>209</sup>
CLN2 / Batten	(x12 by 6 bur holes)	Children	10	AAV2	2.5.10 <sup>12</sup> vg	150 µl	2 µl/min	NCT00151216, Phase I, Radiographical changes in 65% of 60 injections sites	<sup>209</sup>
GAD65 and GAD67 / Parkinson	SubThalamic Nucleus (unilateral)	Adult 25-75 years	12	AAV2	1.10 <sup>11</sup> vg/mL; 3.10 <sup>11</sup> vg/mL and 1.10 <sup>12</sup> vg/mL	50 µl		NCT00195143, Phase I/II, safe; neuroimaging improvement, clinical improvement at 12 months post infusion, decrease of STN activity	<sup>209</sup>
NTN (CERE-120) / Parkinson			58	AAV2	5.4.10 <sup>11</sup> vg			NCT00400634, Phase II, not effective	<sup>208</sup>
GAD65 and GAD67/ Parkinson	SubThalamic Nucleus	Adult 30-75 years	44	AAV2	1.10 <sup>12</sup> vg			NCT00643890, Phase II, well tolerated, improvement at 6 months (not greater than DBS)	<sup>206</sup>
ASPA / Canavan			21	AAV2	1.10 <sup>9</sup> vg				<sup>206</sup>
ASPA Canavan	(X6)	4-83 years	13	AAV2	9.10e11vg			Phase I/II, No longterm adverse event, slowing of disease	<sup>206</sup>

CLN2 / Batten	WM		16	AAV rh.10	9.10 <sup>11</sup> vg (n=6) and 2.85.10 <sup>11</sup> vg (n=10)			NCT01161576, Phase I/II	?
CLN2 / Batten	WM		8	AAV rh.10	9.10 <sup>11</sup> vg and 2.85.10 <sup>11</sup> vg			NCT01414985, Phase I/II	?
NAGLU / MPSIIIB		Child (20-53 months)	4	rAAV2/5	4.10 <sup>12</sup> vg			ISRCTN19853672, Phase I/II, well tolerated, induced sustained enzyme production in the brain, best results in the youngest patients	210
AADC / Parkinson			5	AAV2	9.10 <sup>10</sup> vg			Phase I, Safely tolerated, modest improvement in motor coordination at 6 months (placebo effect ?)	211
AADC / Parkinson			10	AAV2	3.10 <sup>11</sup> vg			Phase I, safe possibly effective	212
SHSH-IRES-SUMF1 / MPSIIIA	12 sites in WM	Child (32-70 months)	4	AAV rh.10	7.2.10 <sup>11</sup> vg	60 µl	2h	NCT01474343 , good tolerance, possible but moderate clinical improvement,	38
AADC / AADC deficiency	Putamen	Child (1.67-8.42 years)	10	AAV2	1.81.10 <sup>11</sup> vg	80 µl /target	3 µl /min	NCT01395641, Phase I/II, motor development improvement in children	35
AADC/AADC deficiency	SN + VTA							NCT02852213, Phase I	NA
CAG-NGF / Alzheimer	Nucleus Basalis Meynert	Adult 50-80 years	10	AAV2				NCT00087789, Phase I, Safe, biologically effective	212
NGF / Alzheimer		Adult >50 years	8					NCT00017940	NA
GDNF	putamen	adult	12	AAV2				NCT04167540 / Phase 1B	NA
GDNF / Parkinson	(x16, 4 in cerebellum)	Adult >18 years	24	AAV2	9.10 <sup>10</sup> vg; 3.10 <sup>11</sup> vg; 9.10 <sup>11</sup> vg and 3.10 <sup>12</sup> vg			NCT01621581, Phase I	NA
ARSA / MLD	12 sites in WM	Child 6-60 months	4	AAV rh.10	1.10 <sup>12</sup> vg/kg (n=2) and 4.10 <sup>13</sup> vg/kg (n=2)	60 µl / site	0,5 µl /min	NCT01801709, Phase I/II	NA
SGSH / MPS IIIA	6 sites in WM	Child	20	AAVrh10				NCT03612869, Phase III	NA
miHTT/Huntington	Intra striatal	adult	26	AAV5	6.10 <sup>12</sup> vg and 6.10 <sup>13</sup> vg			NCT04120493, Phase I/II	NA
AADC		Adults 40 to 75 years	42	AAV2	2,5.10 <sup>12</sup> vg			NCT03562494, Phase II	NA

**Table 7 : Devices for intracerebral gene therapy delivery**

Intracerebral catheter	Developing team/ company	back flow reduction	design	Article
Hamilton Syringe	Hamilton	rigid, steel	endport	
UCSF « homemade »	UCSF, Medgenesis Therapeutics and Brainlab AG	rigid, fused silica, then flexible canna with rigid tip ;	end port, step design	213
Smartflow	MRI Interventions, Inc / UCSF	rigid, ceramic, fused silica liner and a polymer sheath	endport, step design	214
MEMS	Alycone, Inc, Cornell	microfabricated silicon cannula	dual lumen, coupled to multiple proximal tubing	215
Neuroinfuse	Renishaw / Univ Bristol Renishaw Medical Solutions, Neurological Applications Department, New Mills, Wotton-Under-Edge, Gloucestershire GL12 8JR, UK	carbothane	Sub 1 mm diameter catheters and guide tubes	216,217
gliasite / emory University	IsoRay / Emory University	inflatable	balloon tipped, 2, 3, and 4 cm with corresponding full volumes of 5, 15 and 35 cc.	218
hollow fiber	Twin Star Medical		micro-porous	

Cleveland Multiport Catheter	Cleveland Clinic Infuseon Therapeutics	rigid	yes	Multichannel	212
Custom Made Bristol University	Bristol University	rigid	No	One port	219
Barium – impregnated one port infusion catheter	Vygon Valley Forge, PA, USA			one port	212
Barium – impregnated one port infusion catheter	Medtronic		barium impregnated	one port	212

